

**Strengthening Local University
Capacity to Provide Quality Medical
Education and HIV Prevention, Care
and Treatment in Ethiopia under
the President's Emergency Plan for
AIDS Relief (PEPFAR)**

CDC-RFA-GH15-1523

Division of Global HIV/AIDS
Center for Global Health
Centers for Disease Control and Prevention



Contents

Part I. Overview Information	1
A. Federal Agency Name	1
B. Funding Opportunity Title.....	1
C. Announcement Type:.....	1
D. Agency Funding Opportunity Number.....	1
E. Catalog of Federal Domestic Assistance Number.....	1
F. Dates	1
G. Executive Summary.....	1
Part II. Full Text.....	2
A. Funding Opportunity Description	2
1. Background:.....	2
a. Statutory Authorities.....	3
b. Healthy People 2020:	3
c. PEPFAR Priorities and Strategies.....	3
d. Other National Public Health Priorities and Strategies:.....	4
e. Relevant Work:.....	4
2. CDC Project Description	5
a. Approach:.....	5
i. Problem Statement:.....	12
ii. Purpose	13
iii. Outcomes	13
iv. Funding Strategy	14
v. Strategies and Activities.....	14
b. Evaluation and Performance Measurement:.....	18
i. CDC Evaluation and Performance Measurement Strategy:.....	18
ii. Applicant Evaluation and Performance Measurement Plan:.....	35
c. Organizational Capacity of Awardees to Execute the Approach:	35
d. Work Plan:.....	35
e. CDC Monitoring and Accountability Approach	35
f. CDC Program Support to Awardees.....	36
B. Award Information.....	37
1. Type of Award:	37
2. Award Mechanism:.....	37
3. Fiscal Year:.....	37
4. Approximate Total Fiscal Year Funding:.....	37
5. Approximate Total Project Period Funding:	37
6. Total Project Period Length:.....	38
7. Approximate Number of Awards:	38
8. Approximate Average Award:	38
9. Floor of Individual Award Range:	38
10. Ceiling of Individual Award Range:.....	38

11. Anticipated Award Date:	38
12. Budget Period Length:	38
13. Funds Tracking:.....	38
14. Direct Assistance:	38
15. Indirect Costs:.....	39
C. Eligibility Information.....	39
1. Eligible Applicants:	39
2. Special Eligibility Requirements:	39
3. Justification for Less than Maximum Competition:	39
4. Other:	40
5. Cost Sharing or Matching:	40
6. Maintenance of Effort:	40
D. Application and Submission Information.....	40
1. Required Registrations:	40
2. Request Application Package:	41
3. Application Package	41
4. Submission Dates and Times:.....	41
5. CDC Assurances and Certifications:.....	42
6. Content and Form of Application Submission:.....	42
7. Letter of Intent (LOI):	42
8. Table of Contents:	42
9. Project Abstract Summary:	42
10. Project Narrative:	42
11. Work Plan:	44
12. Budget Narrative:	44
13. Tobacco and Nutrition Policies:.....	45
14. Intergovernmental Review:.....	46
15. Funding Restrictions:.....	46
16. Other Submission Requirements:	54
E. Application Review Information	56
1. Review and Selection Process:	56
a. Phase I Review:.....	56
b. Phase II Review:.....	56
c. Phase III Review:.....	59
2. Anticipated Announcement and Award Dates:.....	59
F. Award Administration Information.....	60
1. Award Notices:	60
2. Administrative and National Policy Requirements:	60
3. Reporting:.....	61
a. CDC Reporting Requirements:	61
b. Specific Reporting Requirements:.....	61
i. Awardee Evaluation and Performance Measurement Plan:	61

ii.	Annual Performance Report:	62
iii.	Performance Measure Reporting:	63
iv.	Monitoring Reporting and Evaluation:	63
v.	Federal Financial Reporting:	63
vi.	Final Performance and Financial Report:.....	63
4.	Federal Funding Accountability and Transparency Act of 2006:.....	64
5.	Programmatic Impact Reporting and Monitoring:.....	64
6.	Monitoring and Evaluation:.....	65
7.	Expenditure Analysis	65
8.	Audit, Books, and Records Clause:	65
9.	Reporting of Foreign Taxes.....	67
10.	Human Subjects Restrictions:.....	68
G.	Agency Contacts.....	68
H.	Other Information.....	69
I.	Glossary.....	70

Part I. Overview Information

Applicants must go to the synopsis page of this announcement at www.grants.gov and click on the "Send Me Change Notifications Emails" link to ensure they receive notifications of any changes to CDC-RFA-GH15-1523. Applicants also must provide an e-mail address to www.grants.gov to receive notifications of changes.

A. Federal Agency Name

Centers for Disease Control and Prevention

B. Funding Opportunity Title

Strengthening Local University Capacity to Provide Quality Medical Education and HIV Prevention, Care and Treatment in Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR)

C. Announcement Type:

New-Type 1

This announcement is only for non-research international activities supported by CDC. If research is proposed, the application will not be considered. Research for this purpose is defined at:

<http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>.

D. Agency Funding Opportunity Number

CDC-RFA-GH15-1523

E. Catalog of Federal Domestic Assistance Number

93.067 Global AIDS program

F. Dates

1. Letter of Intent Deadline Date: N/A

Application Deadline Date: October 28, 2014, 11:59 p.m. U.S. Eastern Standard Time, on www.grants.gov

Informational conference call or pre-application workshop if held in person for potential applicants: N/A

G. Executive Summary

1. Summary Paragraph

The purpose of this funding opportunity announcement (FOA) is to enable local Ethiopian universities to contribute to strengthening and improving the quality of HIV/AIDS services in the country. This will be done through building the capacity of the universities to provide quality medical pre-service education, establishment of in-service training units and comprehensive HIV service delivery at the teaching/referral hospitals, clinics, and confidential commercial sex worker clinics in select cases. This FOA intends to ensure continuity of PEPFAR support for university hospitals and clinics at Addis Ababa, Hawassa, Jimma and Mekelle Universities.

The universities will support and collaborate with their respective Regional Health Bureaus (RHBS), the Network of Networks of HIV Positives (NEP+), and other stakeholders in the implementation of HIV/AIDS related activities. This award targets the university community at large and the catchment area populations that use the services provided by the university teaching hospitals and clinics.

a. **Eligible Applicants:** Limited Eligibility Competition

b. **FOA Type:** Cooperative Agreement

c. Approximate Number of Awards: 4
d. Total Project Period Funding: None
e. Average One Year Award Amount: \$675,000.00 for Hawassa University \$775,000.00 for Jimma Universities \$800,000.00 for Addis Ababa University \$1,750,000.00 for Mekelle University
f. Number of Years of Award: 5 Years
g. Approximate Date When Awards will be Announced: February 2015
h. Cost Sharing and /or Matching Requirement: N/A

Part II. Full Text

A. Funding Opportunity Description

1. Background:

The President’s Emergency Plan for AIDS Relief (PEPFAR) has called for immediate, comprehensive and evidence based action to turn the tide of HIV/AIDS. As part of the PEPFAR goals and principles and in alignment with the USG roadmap (“the Blueprint”) for achieving an AIDS free generation, PEPFAR Ethiopia is in the process of transitioning facility-based comprehensive HIV care and treatment services from international implementing partners to local government and non-governmental entities to ensure local ownership and long term sustainability of HIV services in Ethiopia.

Ethiopia has a mixed HIV epidemic with low prevalence (0.6%) in the rural areas and generalized concentrated epidemic (4.2%) in urban areas. HIV prevalence is high in the major urban cities like Addis Ababa (5.2%); Mekelle (3.1%); Hawassa (1.9%) and Jimma (1.8%). Additionally, HIV prevalence among high risk populations such as commercial sex workers (CSWs) located in these major urban cities is also high (25%). Taking into consideration the Federal Ministry of Health’s (FMOH) adoption of the 2013 World Health Organization (WHO) guidelines (treating all TB/HIV patients, treating all children under the age of 15 and treating all HIV positive patients with CD4 count less than 500), the number of patients eligible for antiretroviral therapy (ART) is expected to increase from 383,960 to 464,520 by 2015. This increase has the dual benefits of ART as prevention and mitigation of the impact of HIV. As most of the disease burden is in the urban areas, the local universities and their associated teaching hospitals which serve high volumes of HIV patients and which are located in these cities, will continue to play a critical role in creating access to ART services.

Additionally, to meet these goals and build sustainable human resource capital, PEPFAR will support the training of new medical doctors in HIV/AIDS prevention, treatment and care through the local universities. This funding opportunity announcement (FOA) intends to support both medical pre-service education and establishment of in-service training units in Jimma and Mekelle Universities. For those universities supported by the Medical Education Partnership Initiative (MEPI), namely Addis Ababa University and Hawassa University, this FOA will provide support to establish in-service training units.

This program supports the goals of the Government of Ethiopia’s (GoE) National Strategic Plan II, and aligns with the goals of the GOE and USG HIV/AIDS Partnership Framework and the Global Health Initiative by targeting geographically high risk urban areas and high priority/risk populations groups including People Living With HIV (PLHIV) and commercial sex workers (CSWs).

This FOA intends to ensure continuity of PEPFAR support for university hospitals and clinics at Addis

Ababa, Hawassa, Jimma and Mekelle Universities; improve the quality of integrated HIV services at these facilities; build on the progress made through previous cooperative agreements to strengthen the universities' capacity to improve the quality of medical education; and consolidate the support to Regional Health Bureaus (RHBs) in providing in-service training to improve quality of HIV interventions in their respective regions.

a. Statutory Authorities

This program is authorized under Public Law 108-25 (the United States Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, et seq.] and Public Law 110-293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113-56 (PEPFAR Stewardship and Oversight Act of 2013).

The President's Emergency Plan for AIDS Relief (PEPFAR) has called for immediate, comprehensive and evidence based action to turn the tide of global HIV/AIDS. The overarching purpose of this FOA is to fund activities to prevent or control disease or injury and improve health, or to improve a public health program or service. Recipients may not use funds for research. Certain activities that may require human subjects review due to institutional requirements but that are generally considered not to constitute research (e.g., formative assessments, surveys, disease surveillance, program monitoring and evaluation, field evaluation of diagnostic tests, etc.) may be funded through this mechanism.

b. Healthy People 2020:

Healthy People 2020 provides national health objectives for improving the health of all persons by encouraging collaborations across sectors, guiding individuals toward making informed health decisions, and measuring the impact of prevention activities. Additional information on Healthy People 2020 is available at <http://www.healthypeople.gov>.

c. PEPFAR Priorities and Strategies

Under the leadership of the U.S. Global AIDS Coordinator, as part of the President's Emergency Plan, the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (HHS/CDC) works with host countries and other key partners to assess the needs of each country and design a customized program of assistance that fits within the host nation's strategic plan and partnership framework.

HHS/CDC focuses primarily on two or three major program areas in each country. Goals and priorities include the following:

- Achieving primary prevention of HIV infection through activities such as expanding confidential counseling and testing programs linked with evidence based behavioral change and building programs to reduce mother-to-child transmission;
- Improving the care and treatment of HIV/AIDS, sexually transmitted infections (STIs) and related opportunistic infections by improving STI management; enhancing laboratory diagnostic capacity and the care and treatment of opportunistic infections; interventions for intercurrent diseases impacting HIV infected patients including tuberculosis (TB); and initiating programs to provide anti-retroviral therapy (ART);
- Strengthening the capacity of countries to collect and use surveillance data and manage national HIV/AIDS programs by expanding HIV/STI/TB surveillance programs and strengthening laboratory support for surveillance, diagnosis, treatment, disease monitoring and HIV screening for blood safety; and
- Developing, validating and/or evaluating public health programs to inform, improve and target

appropriate interventions, as related to the prevention, care and treatment of HIV/AIDS, TB and opportunistic infections.

In an effort to ensure maximum cost efficiencies and program effectiveness, HHS/CDC also supports coordination with and among partners and integration of activities that promote Global Health Initiative principles. As such, grantees may be requested to participate in programmatic activities that include the following activities:

- Implement a woman- and girl-centered approach;
- Increase impact through strategic coordination and integration;
- Strengthen and leverage key multilateral organizations, global health partnerships and private sector engagement;
- Encourage country ownership and invest in country-led plans;
- Build sustainability through investments in health systems;
- Improve metrics, monitoring and evaluation; and
- Promote research, development and innovation (research is not supported by this FOA).

This announcement is only for non-research activities supported by CDC. If research is proposed, the application will not be reviewed. For the definition of research, please see the CDC Web site at the following Internet address: <http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

d. Other National Public Health Priorities and Strategies:

N/A

e. Relevant Work:

N/A

2. CDC Project Description

a. Approach:

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
Facility-Based Antiretroviral Therapy (ART) Services			
Goal: To ensure the quality, continuity, ownership and transition of the ART program			
Undertake mentoring of teaching hospital healthcare providers including case discussions on patients receiving ART	Improved skills of health care providers, continuous and uninterrupted provision of ART services at teaching hospitals	Increased ART services	Improved access to ART services
Provide ART in-service trainings to nurses, health officers and physicians		Reduced attrition of health officers and nurses	Decreased shortage of human resources for ART service delivery
Establish and strengthen a functional multi-disciplinary team (MDT) to oversee HIV/AIDS activities	Improved comprehensive ART services	Decreased loss to follow up of patients from ART	Improved continuum of care provided
Participate in catchment area meetings to discuss HIV/AIDS service challenges and solutions	Improved referral system and health network of teaching hospitals and health facilities within the catchment area	Increased sustainability of ART services	
Ensure linkages and referrals of PLHIV to care and treatment	Improved comprehensive ART services	Improved continuum of care provided	
Recording and reporting of ART activities in the teaching hospitals and confidential clinics	Increased capacity to generate quality data	Increased use of site level data for performance monitoring	Increased use of site level data for program quality improvement
Mekelle University will provide ARV services to commercial sex workers (CSWs) through its confidential clinics	Increased access to ART among CSWs	Increased integrated HIV services for CSWs	Improved health status of HIV infected CSWs
Under take ART adherence and retention in care activities (in collaboration with NEP+	Improved adherence counseling of case managers and healthcare providers to patients taking ART and tracing of lost to follow up ART patients	Decrease in lost to follow up of ART patients	Decreased mortality and improved health status of PLHIVs taking ART

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
Collaborate with RHBs in program activities such as mentoring, in-service training, supervision and program evaluation	Improved working relationship between RHBs and local universities	Improved collaboration between RHBs and local universities	RHBs and local universities make decisions based on evidence on a regular basis
Hire relevant staff to plan, implement and monitor ART programs	Improved effectiveness and efficiency of ART program implementation	Improved program management	Improved program monitoring and evaluation
Implement post exposure prophylaxis (PEP) services at teaching hospitals	Improved access to biomedical HIV prevention	Decreased incidence of HIV among the catchment population	Decreased prevalence of HIV among the catchment population
Undertake minor renovation of ART clinics	Improved infrastructure at ART clinics which supports improved service delivery	Improved working environment at ART clinics	Improved quality of ART services
Distribute and ensure continuous supply of job aids, reference materials and SOPs	Increased use of relevant job aids, reference materials and SOPs	Increased compliance of healthcare providers with the national ART guidelines in the provision of ART services	Improved clinical practice in ART service delivery
Organize and support HIV/AIDS teams at colleges of medicine and health sciences to provide site level ART technical assistance	Increased technical support to teaching hospitals' ART clinics in the form of mentoring and supervision	Improved quality of ART services	Ownership for sustainable implementation of ART Improved quality of ART services Improved use of site level ART data for program decision making
Implement quality improvement (QI) activities	Improved quality of ART services		
Monitor the ART program using MER indicators	Increased utilization of MER monitoring data and program reviews to improve program implementation		
HVOP Goal: To strengthen the university health facility's capacity to implement effective HIV and sexually transmitted infection (STI) prevention activities for most at risk and high priority populations			
Provide on-site STI trainings for health care workers (HCWs)	Increased number of HCWs trained on STIs	Improved quality of STI diagnosis and treatment services at facility level Improved skills of HCWs on the	Standardized quality and efficient STI services provided at the university health facilities

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
		management of STIs	Improved quality of STI/HIV services to high risk and high priority populations
Test STI patients for HIV and link HIV positive clients to care and treatment services in the health facilities	Increased access of HIV counseling and testing among STI patients	Increased HIV testing and linkage of STI patients diagnosed with HIV into HIV care and treatment services	
Provide STI diagnosis and treatment services for STI patients and PLHIV in family planning (FP), antenatal care (ANC), ART and other clinics at university health facilities	Increased STI cases detected and treated at FP, ANC, ART and other clinics in year one	Improved quality of STI/HIV services and service integration at facility level	
Provide condoms to STI patients and PLHIV seen at university health facilities	Increased access to condoms for STI patients and PLHIV	Improved consistent and correct utilization of condoms by STI patients and PLHIV	
Provide risk reduction counseling of STI patients at university health facilities	Increased access to individual risk reduction counseling among STI patients	Decreased multiple sexual concurrent partners among STI patients Increased condom use among STI patients and PLHIV	
Print and distribute STI job aid materials such as national STI guidelines, wall charts and flip charts as well as IEC/BCC materials on STI/HIV prevention	Increased availability of STI job aid materials in the health facilities and with clients	Improved quality of STI/HIV diagnosis and treatment services	
Confidential CSW Clinics in Mekelle, Adigrat and two other hot spot areas in Tigray Region			
Provide STI screening, diagnosis and treatment services and increase condom access for CSWs and their partners	Increased access of CSWs and their partners to STI screening, testing and treatment , and to condoms	Reduction in incidence and prevalence of STIs among CSWs and their partners	Standardized quality and efficient STI service package provided
Provide HCT services for CSWs	Increased access of CSWs to HIV testing	Increased detection of HIV positive cases among CSWs	
Provide ART services for HIV positive CSWs at the confidential clinics	Increased availability of ART services at two CSWs clinics	Improved quality of life for HIV positive CSWs	Improved quality of STI/HIV and ART services to key populations (CSWs)
Provide risk reduction counseling to CSWs	Increased individual risk reduction counseling among CSW	Improved safe sex practice through consistent and correct condom use	

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
Expansion of user friendly CSWs clinics	Increased access of CSW friendly services in high HIV/STI prevalence locations	Improved access and quality of STI/HIV diagnosis and treatment services to CSWs	
PDCS and PDTX			
Goal: To successfully transition the technical and management support for the site level implementation of comprehensive pediatric HIV care and treatment services in the university hospitals of the respective local universities to ensure sustainability and local ownership			
Arrange training and experience sharing opportunities for the university's project teams to improve managerial, supervisory and project management skills	Increased managerial, organizational, supervisory and project management skills of the project staff	Improved institutional capacity for project management and implementation of site-level support	Improved contribution to achieving the national target of 95% coverage for pediatric ART
Support targeted testing at various entry points for children and testing and expanded testing for HVCs and children of adult HIV clients	Increased number of infected infants and children who are identified early are provided with care and treatment services	Increased adherence of health workers in the ARRT clinics to standard guidelines and tools in the provision of pediatric care and treatment	
Provide site-level mentoring and technical assistance to improve the quality care and treatment services for HIV exposed/infected infants children and adolescents	Improved capacity of HCWs to provide care and treatment services in ART clinics	Increased enrollment of HIV exposed and infected children in pediatric ART and care	Improved quality of life for HIV infected children receiving pediatric HIV services in the university hospitals Reduced mortality and morbidity among infant and children receiving pediatric HIV services in the university hospitals
Furnish ART clinics and distribute necessary supplies, national guidelines, job aids, reference materials and SOPs required for the provision of pediatric HIV services	Improved set up to provide pediatric HIV care and treatment services	Improved quality of care and treatment services provided for HIV exposed and infected children in the university hospitals	
Conduct training for health care providers on pediatric care and treatment services	Increased knowledge and skills of health care providers in pediatric care		
Support the implementation of psychosocial care and support services for children and adolescents in ART clinics	Increased access by HIV exposed or infected infants, children and adolescents to psychosocial care and support services		

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
Ensure that sites implement HIV exposed infants HEI care including the prompt linking of early infant HIV diagnosis and positive children to HIV care and treatment	Improved HEI care and infant testing and linkage according to the national standard		
Initiate utilization of quality improvement tools in the ART clinic	Improved practices to ensure quality of pediatric HIV services in the ART clinics		
Utilize case managers for adherence counseling and tracking of lost to follow-up HEIs and HIV infected children	Increased retention in care of HEIs and infected children		
Liaise with community level partners to improve uptake and adherence of HEI and HIV infected children	Enhanced linkages between the hospital and community based programs		
Liaise with relevant partners to ensure rollout, implementation and monitoring of pediatric preventive care packages	Reduced incidence of opportunistic and other infections among HIV infected children		
Conduct program evaluations for pediatric HIV care and treatment implementation	Evidence generated at site level and used by stakeholders for program improvement		
Collect, compile and report site level data for the PEPFAR MER indicators	Improved monitoring and reporting of site level data to CDC according to CDC requirements		
PMTCT			
Goal: To contribute to the elimination of new pediatric HIV infections and improve maternal, newborn and child health			
Provide HCT to women receiving care at ANC, labor and delivery (L&D) and postpartum	Increased uptake of HCT among pregnant women	Improved HIV testing coverage among pregnant women	Increased contribution towards achievement the national e-MTCT targets
Provide ART for HIV-infected women during pregnancy, delivery, and breast feeding under the countries new guideline of PMTCT Option B+	Increased access to ART among HIV-infected pregnant women to reduce the risk of MTCT	Improved ARV coverage among HIV-infected pregnant women	

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
Provide ARV prophylaxis to (HEIs) to reduce the risk of MTCT	Increased access to ARV prophylaxis among HEIs to reduce the risk of MTCT	Improved ARV prophylaxis coverage among HEI	
Provide virological tests to HEIs within 2 months of birth	Increased access of HEIs to virologic tests within 2 months of birth	Improved coverage of virological tests within 2 months of birth for HEIs	Increased early identification and treatment of HIV infected children
Provision of testing to HEI after the exposure to HIV has ended (i.e. after breastfeeding)	Improve the coverage of testing after exposure to HIV for HEI	Increase the identification of children infected with HIV	Improve survival of children infected with HIV
Ensure that HEIs have a final diagnosis documented	Increase retention of HEIs in PMTCT services	Increase retention of HEIs in PMTCT services	Improved continuum of care provided to HEIs
Ensure linkages and referrals of children living with HIV to care and treatment	Improved comprehensive ART services for infected infants	Improved continuum of care	Improved quality of PMTCT services
Implement quality improvement activities in PMTCT settings	Improved quality of PMTCT services	Improved quality of PMTCT services	Improved quality of PMTCT services
Recording and reporting of PMTCT activities in the teaching hospitals and confidential clinics	Increased capacity to generate quality data	Increased use of site level data for performance monitoring	Increased use of site level data for program quality improvement
Provide PMTCT in-services trainings to nurses, health officers and physicians	Improved skills of health care providers, continuous and uninterrupted provision of PMTCT services at teaching hospitals	Increased PMTCT services	Improved access to PMTC services
Hire relevant staff to plan, implement and monitor PMTCT programs	Improved effectiveness and efficiency of PMTCT program implementation	Improved program management	Improved program monitoring and evaluation
Establish and strengthen a functional multi-disciplinary team (MDT) to oversee PMTCT activities	Improved comprehensive PMTCT services	Decreased loss to follow up of patients from PMTCT services	Improved continuum of care provided
Collaborate with RHBs in program activities such as mentoring, in-service training, supervision and program evaluation	Improved working relationship between RHBs and local universities	Improved collaboration between RHBs and local universities	RHBs and local universities make decisions based on evidence on a regular basis

<u>Activities</u>	<u>Outcomes</u>		
	<u>Short Term Outcomes (1-2 Years)</u>	<u>Intermediate Outcomes (3-4 Years)</u>	<u>Long Term Outcomes (5+ Years)</u>
Monitor the PMTCT program using MER indicators	Increased utilization of MER monitoring data and program reviews to improve program implementation	Improved utilization of data to inform the program	Improved quality of PMTCT services
Human Resources for Health (HRH)			
Goal: To increase production, and improve the quality and retention of medical graduates with skills to address the HIV care and treatment and other health needs of the country, ultimately improving the health outcomes of the population			
Provide support for pre-service medical education increase the number of graduates and the quality of education	Increased appropriate competencies among medical graduates to provide HIV care and treatment services	Improved quality of medical education	Improved quality of HIV and other health services
Establish a network of medical schools to share academic resources, including instructors	Increased understanding among medical schools of the importance of networking	Increased number of medical schools share their academic resources within the network	Enhanced culture of professional development and continuous quality improvement in medical schools
Establish in-service training units to manage, coordinate and provide trainings in a sustainable manner	Increased access to high quality HIV/AIDS in-service training for HIV care providers	Improved performance of health providers	HIV/AIDS related in-service trainings at local universities are technically and managerially sustained
Develop in-service training M & E system	Increased in knowledge and engagement in tracking in-service training data and reporting	Improved in-service training data utilization for planning and standardization	Quality of HIV related in-service training improved

i. Problem Statement:

This FOA is intended to help address HIV prevention and care and treatment needs in Ethiopia, as well as the acute lack of trained health care workers in the country. Quantification of the problem for the areas to be supported under this FOA is provided below.

ART: Ethiopia has a mixed HIV epidemic with low prevalence (0.6%) in the rural areas and generalized concentrated epidemic (4.2%) in urban areas. HIV prevalence is high in the major urban cities like Addis Ababa (5.2%), Mekelle (3.1%), Hawassa (1.9%) and Jimma (1.8%). Additionally, HIV prevalence among high risk populations such as commercial sex workers (CSWs) located in these major urban cities is also high (25%). Given the FMOH's adoption of the 2013 WHO treatment guidelines, the number of patients eligible for ART is expected to increase from 383,960 to 464,520 in 2015. Ensuring increased capacity for delivery of quality ART services will be required to meet the increased need.

HVOP: A strong link exists between STIs and HIV infection with many studies demonstrating that STIs are a co-factor for HIV transmission. Recent study shows that HIV prevalence among Key population (CSWs) in Ethiopia is 25%. Management and treatment of STIs can play an important role in the reduction of HIV transmission, especially in high-risk populations such as CSWs. Major urban towns serving thousands of high priority and high risk populations. To be able to implement comprehensive STI/HIV prevention care and treatment services at the university health facilities is vital. An estimated 10, 000 CSWs are targeted to be reached with comprehensive STI/HIV and those positive for HIV will get ART service in all four confidential sex workers clinics under Mekelle University.

PDCS and PDTX: National ART coverage for pediatric care and treatment (21%) lags far behind adult ART coverage. As of September 2013, the four university hospitals combined have over 800 children current on ART (as per APR data). As Ethiopia is in the process of adopting the 'test and treat' approach for all children less than 15 years of age, the number of children eligible for ART is expected to increase. Moreover, the care and support services available for children and adolescents in care need to be reinforced to ensure provision of comprehensive HIV services. To ensure a successful transition of the program and to build on achievements made to date, the universities must strengthen their technical and managerial capabilities to provide site level support for pediatric care and treatment activities.

PMTCT: In FY2013, PEPFAR-supported PMTCT sites detected 62.7% of the estimated number of HIV+ pregnant women (PW) in Ethiopia, of whom 84.5% were covered with ARVs. Late in FY2013, Option B+ was introduced, and by FY2014 was widely implemented. Ethiopia has launched its e-MTCT plan in November, 2013. Ethiopia is expected to build on this success to reach elimination targets by COP15. Critical to achieving these targets will be the successful transition of site level support from international partners to the country's RHBs and local universities.

HRH: Ethiopia faces a severe lack of trained health care workers. In 2008 it was estimated that there were 0.86 health care workers per 1,000 people - far from the benchmark of 2.28 health care professionals per 1,000 people. The physician-to-population ratio (0.03 per 1,000 people) has worsened over the last two decades due to an increase in the attrition rate of medical doctors, fast population growth, governmental and non-governmental health institution expansion, and low production of doctors. This lack of trained health professionals limits the capacity of implementing quality HIV interventions, along with other priority health needs of the

population.

ii. Purpose

This FOA will address the problem statement by strengthening the universities technical and management capabilities to manage, monitor, coordinate, and implement evidence-based comprehensive HIV/AIDS programs; ensuring continuity and improved quality of HIV care and treatment services at the university teaching hospitals which serve high volumes of HIV patients; supporting HIV prevention activities among high-risk populations; increasing the production, quality and retention of medical graduates with skills to address the HIV/AIDS care and treatment needs; and improving the skills of HCWs through consolidated support to RHBs in providing in-service training.

iii. Outcomes

Key outcomes to be achieved by the end of the project, by program area, are shown below.

ART:

- Increased numbers of PLHIV in need of ART receive the service
- More health care providers are trained on ART
- Improved health outcome of patients receiving ART.
- Reduced loss to follow up of patients receiving ART
- Ensured continuum of care
- Improved referral linkages
- More high-risk persons get ARV services
- Improved quality of life of PLHIV
- Reduced HIV incidence
- ART program continuity ensured

HVOP:

- Standardized quality and efficient STI service package provided to high priority populations and the university hospital and health facilities
- Improved quality of STI/HIV and ART services to key populations (CSWs)

PDCS and PDTX:

- Increased contribution to the national target of 95% coverage for pediatric ART
- Improved quality of care and treatment services for HEIs and HIV infected children

PMTCT: Measurable outcomes below pertain to years three through five of the project period. Measurable outputs below are annual targets as per Ethiopia CDC Country Operational Plan to be completed by the end of the project year.

- 95% uptake of counseling and testing among all pregnant women
- 95% of HIV-infected pregnant women receive ART to reduce the risk of MTCT
- 95% of HIV exposed infants receive ARV prophylaxis to reduce risk of MTCT.
- 95% of HEI receive virologic tests within 2 months of birth

HRH:

- Increased number of medical graduates from pre-service training institutions
- Increased number of students retained in pre-service medical education programs
- Increased number of in-service training units established
- Increased number of health professionals receiving HIV/AIDS related in-service trainings

- Monitoring systems established to supervise quality of pre-service education and in-service training

To the extent funding activities lead to training materials, tools, etc., applicants should be aware that at the end of the project period, training materials will be maintained by the local universities themselves and shared with Regional Health Bureaus, the Federal Ministry of Health, and CDC-Ethiopia.

iv. Funding Strategy

N/A

v. Strategies and Activities

ART Services:

Local universities under this award will undertake the following activities related to ART:

- Ensure delivery of quality ART services in its hospital by conducting in-service trainings of nurses, health officers and physicians as well as mentoring, organizing multi-disciplinary team (MDT) meetings, and addressing gaps when they arise.
- Participate in joint site supervisions, catchment area meetings and ensure inter- and intra-facility referral linkages in collaboration with RHBs.
- Support analysis and use of reports and data for improved service in the facilities.
- Collaborate with RHBs in areas of training, mentoring, supervision and program evaluation.
- Conduct program evaluations to generate data and improve performance of the HIV/AIDS program within the hospital and catchment areas.
- Collaborate with PEPFAR implementing partners, including NEP+, an umbrella network of PLHIV associations in Ethiopia, to ensure adherence and retention to ART through case managers.
- Organize HIV/AIDS team at college of medicine and health sciences. Recruit additional man power to manage the ART program.
- Undertake minor renovation of ART clinics based on assessments of the facilities and their needs.
- Distribute and ensure continuous supply of job aids, reference materials and SOPs.
- Undertake case discussions and conduct quarterly review meetings.
- Mekelle University will provide ARV service to CSWs using its own confidential clinics.
- Implement PEP service.

HVOP:

Local universities under this award will undertake the following activities related to STI:

- Strengthen the capacity of HCWs under the university to diagnose and treat STI/HIV cases, and train the HCW's on syndromic management of STIs.
- Test STI patients for HIV through the provision of provider-initiated testing and counseling (PITC) and the university facilities in collaboration with RHBs. At least 80% of STI patients will be tested for HIV and linked to care and treatment services.
- Provide STI screening and diagnosis services for PLHIV at ART clinics and provide treatment for those who are positive for STIs.
- Provide STI diagnosis and treatment along with FP and ANC services at university health facilities.
- Promote, demonstrate and ensure access to condoms for clients of university health facilities, particularly for STI patients and PLHIV.

- Provide risk reduction counseling for STI patients at health facilities under the universities.
- Support the capacity of health facilities under the universities to print and distribute STI job aid materials such as national STI guidelines, wall charts, and flipcharts, as well as IEC/BCC materials on STI/HIV prevention.
- Increase access to prepackaged STI treatment kits in the health facilities under in the universities.
- Reach high priority populations with evidence based minimum STI/HIV prevention and treatment package of services at all health facilities. These include Black Lion Hospital and 7 student clinics in different campuses.
- CSW STI clinic activities:
 - Strengthen the two CSW clinic's services in Mekelle and Adigrat towns.
 - Provide regular monthly STI screening, diagnosis and treatment to CSWs and their partners at the two CSW clinics.
 - Provide regular biannual HCT service to CSWs at the two confidential CSW clinics.
 - Provide ART services for HIV positive eligible CSWs at the confidential clinics.
 - Promote and provide condoms to CSWs at the confidential CSW clinics.
 - Support the provision of FP services to CSWs at the two confidential CSW clinics through collaboration with other PEPFAR partners including FGAE.
 - Establish support groups for HIV positive clients at the confidential CSW clinics.

PDCS and PDTX:

Local universities under this award will undertake the following activities related to PDCS and PDTX:

- Support targeted HIV testing for children via PICT at under-five clinics, pediatric inpatient services, TB clinical and the OVC population.
- Strengthen family-focused HTC, care and treatment, and linkages to other services.
- Provide site-level support through mentoring at the ART clinic in the university hospital to improve service quality and provide onsite updates for providers.
- Provide supplies, equipment, IEC materials/job aids.
- Conduct in-service training for health care providers on pediatric care and treatment services.
- Support implementation of psychosocial care and support for children and adolescents addressing their psychological and spiritual needs.
- Provide technical support to strengthen the management of HEIs and HIV infected infants and early treatment for HIV-infected infants per national guidelines.
- Initiate and strengthen utilization of quality improvement tools to identify and respond to gaps in service provision at health facilities.
- Integrate case managers into pediatric ART units to ensure retention, tracking and referral for support services to available community based organizations.
- Liaise with community level partners to support uptake and adherence of HEIs and pediatric patients and link to OVC programs for identification of HIV exposed and infected children.
- Conduct MDT meetings to strengthen referrals to and from various HIV care points in the hospital.
- Participate in catchment area meetings to coordinate referrals to and from other facilities.
- Coordinate with the relevant partner to ensure rollout, implementation and monitoring of pediatric preventive care package including utilization of cotrimoxazole prophylaxis, TB screening, malaria prevention and treatment (including ITNs), prevention and treatment of diarrhea, linkages to immunization programs, and Isoniazid prophylaxis (IPT) for HIV

positive children, and promote healthy hygiene & safe water interventions.

- Strengthen adolescent care and treatment activities.
- Collect, compile and report site level data using MER indicators.
- Conduct program evaluation to generate information that helps to improve support to facilities.

PMTCT:

The recipient of these funds is responsible for activities in PMTCT program areas designed to target pregnant women and their partners receiving health care services at the respective university hospitals and affiliated satellite clinics. Local universities under this award will undertake the following activities related to PMTCT:

- Strengthen capacity of the university medical schools, department of obstetrics and gynecology, to undertake PMTCT activities and expand coverage.
- Support implementation PMTCT services at university hospitals following the national PMTCT guidelines (Option B+ approach), including opt-out HIV testing and counselling and provision of ART for women and ARV prophylaxis for HIV-exposed infants.
- Support health facilities to improve performance of Early Infant Diagnosis (EID) including ensuring virological testing for HEIs within 2 months of birth, re-testing of HEIs after the exposure to HIV has ended, linking infected infants to care and treatment, and reporting results.
- Promote QI activities through use of site performance data and QI approaches and provision of job aids.
- Assure quality of data collected at facilities through the use of the updated PMTCT M&E tools and assure PEPFAR indicators are systematically collected and reported to PEPFAR and FMOH.
- Support “real time” monitoring and reporting on PMTCT indicators as well as drug or critical lab stock outs.

HRH:

Local universities under this award will undertake the following activities related to HRH:

- Improve the quality of medical education and retention of students. The activities include faculty development, improving skill laboratories, strengthening e-learning systems, securing sufficient teaching equipment and books, organizing extra tutorial sessions for students, and development of a performance monitoring system.
- Establish a network of medical schools: Build the capacity of academic staff through establishment of resource centers; exchange faculty to improve the transfer of skills in teaching student assessment and instructional design development. The network will extend support to the new medical schools and Integrated Emergency Surgical & Obstetrics Officers (IESO) training.
- Establish and consolidate local university’s in-service training (IST) units in partnership with ICAP and CDC. The unit will collaborate with the respective RHB to develop annual IST plan based on identified needs and priority of HIV/AIDS contents and establish a business relationship.
- Strengthen training information systems to monitor IST implementation and utilize information for decision making.

1. Collaborations:

Local universities are required to collaborate with the following organizations:

- Regional Health Bureaus (RHBs): Local universities will collaborate with RHBs on the provision of HIV prevention activities including STI and HCT services in the university

facilities. These activities include supplies for STI and HCT, training joint site visits, technical assistance as required and harmonious implementation of STI and HCT program, monitoring and evaluations.

- Columbia ICAP (ICAP): Local universities will collaborate with ICAP to coordinate HIV prevention (STI, HCT) activities at the universities health facilities.
- Population Services International (PSI) and Pharmaceutical Funds and Supply Agency (PFSA): PSI and PFSA are involved in STI treatment kitting and distribution to public, NGO and private health facilities. Local universities are expected to coordinate activities with PSI and PFSA for STI drug supply and job aids.
- Family Guidance Association of Ethiopia (FGAE): Local universities will collaborate with FGAE to leverage sexual and reproductive health (SRH) services and commodities to CSW clinics.
- The American International Health Alliance-Twining Center (AIHA-TC): AIHA-TC will strengthen human and organizational capacity of local institutions. AIHA-TC will build institutional and human resource capacity in the field of biomedical engineering and technology as an important component of health systems strengthening.

2. Target Populations:

Local universities teaching hospitals serve a catchment area of approximately 5,000,000 people. The university hospitals are in urban areas with higher HIV prevalence and provide critical services. By the end of FY 2013, a total of 5,358 female and 3,616 male PLHIV were receiving ART as well as more than 800 children at the four local universities teaching hospitals. Under this award the local universities will continue to support the provision of ART service to PLHIV per epidemiology of the disease and ART need. Additionally, these hospitals serve referral cases from lower level facilities. University health facilities provide STI services to in the campus community, staff and students as well as the surrounding community.

Studies show that HIV prevalence among CSWs in Ethiopia is significantly higher than the general population – as high as 25% in some major urban areas. This FOA will target CSWs with the provision of STI/HIV services through the confidential CSW clinics.

Populations targeted for pre-service medical education are medical students, local university faculty and networked institutions. HIV care providers, health care workers, program managers and/or coordinators are targeted for in-service training activities.

Inclusion:

N/A

b. Evaluation and Performance Measurement:

i. CDC Evaluation and Performance Measurement Strategy:

CDC Ethiopia will monitor the performance of the awardees through semiannual and annual reports. Awardee project reports, reviewed by CDC Ethiopia, will adhere to OGAC guidance and timelines. CDC Ethiopia will review data submitted by partners, validate and submit to CDC Atlanta. CDC Ethiopia recommends that 5-10% of the budget be dedicated for evaluation and performance measurement.

Progress reports will be based on MER indicators and if need be CDC program, M&E staff and the awardee together will select additional non PEPFAR and/or MER level 2 and/or other recommended indicators. The MER indicators listed in the table below will be reported by the Awardees.

CDC Ethiopia will work with the awardees to demonstrate program impact through process and outcome or impact evaluations of funded activities. Process evaluations will be used to assess the extent to which planned activities have been implemented and lead to feasible and sustainable programmatic results. Outcome/ impact evaluations will be external and used to assess whether funded activities are leading to intended outcomes including public health impact for an AIDS Free Generation. Protocols for evaluation should be submitted to CDC ADS for determination and approval.

Quality will be operationally defined and composite indicators will be used to measure quality. Routine service data records and primary data collected from patients, service providers, key and informants and on site observation data sources will be utilized during the suggested evaluations.

The local university will conduct joint site visits with CDC Ethiopia team to see the actual performance at the site level on an annual basis, and should conduct their own site visits to health facilities quarterly. These will be based on the guideline of CDC site monitoring visits using core essential elements to see the actual performance at site level. Following site visits, action plan development will be done and based on the level of gaps identified; follow on visit will be done to ensure information use and improvement. Other STI /HIV survey and surveillance activities will be used to further evaluate/triangulate the outcomes of the program.

For evaluation of the ART component of the project, two questions will be addressed: (1) What is the rate of patient retention after the ART program is transitioned to local universities? (2) Did the rate of newly enrolled ART patients increase as a result of the activities implemented under this FOA? Data sources will include SAPR, APR and review of patient charts at the ART clinics. Rate of retention and newly enrolled ART patients will be compared with the baseline data before the transition. MOH, FHAPCO, RHBS, local universities, CDC Ethiopia and CDC Atlanta will be involved in the evaluation. CDC Ethiopia in collaboration with local universities will assist with protocol development and conduct of the evaluation while CDC Atlanta provides overall guidance. MOH, FHACPO and RHBs will participate throughout, giving guidance, approval, feedback and

ultimately use of the data for ART program improvement. The findings of the evaluation will be disseminated via symposia, workshops, meetings and local journals.

According to the HRH strategic plan of MOH the selected priority HRH categories of Pre-Service Training (PST) scale up include medical doctors to fill the prevailing critical shortage in the country. To this effect, several initiatives including increasing student enrollment in the existing medical schools as well as postgraduate studies to produce more qualified instructors . However, these initiatives are being threatened by several challenges including shortage, high attrition and poor skill mix of existing faculty, inadequate teaching facilities and materials and lack of appropriate technology. In addition to the existing effort by the government, CDC/PEPFAR and its implementing US University partners have been supporting local university partners in addressing these challenges in their respective areas of operation. Pre-service training program has been supported in the past at Addis Ababa, Hawassa, Jimma and Mekelle Universities through US based implementing partners. These universities have the capacities to manage their own medical education activities with minimal technical and financial support from PEPFAR. In-service training has been established in these universities as part of the MOH effort to institutionalize and standardize in-service training in the country. The units are at the infancy stage and require PEPFAR to strengthen their capacity. During the next project period, these universities will develop a business model to generate income for future sustainability. The related evaluation question is: How effective are the sustainability building strategies for the medical education pre-service program and in-service training units upon completion of this FOA? Throughout the project period the MER indicator for tracking the progress of pre-service programs is (H2:1D) Number of new health care workers who graduated from a pre-service training institution during the reporting period. Additionally, program performance reports for pre-service training, site assessment and CDC oversight will be used to monitor program implementation

CDC Ethiopia will use overall evaluation findings during the five-year FOA period to establish key recommendations for partners on program implementation and effectiveness, sustainability, and continued program improvement upon completion of the award.

<u>Addis Ababa University MER Indicators</u>	<u>2015</u>
Number of PEPFAR-supported DSD and TA sites	8
By program area/support type: Treatment Direct Service Delivery (DSD)	1
By program area/support type: PMTCT Direct Service Delivery (DSD)	1
By program area/support type: General Population Prevention Direct Service Delivery (DSD)	7
By program area/support type: General Population Prevention Technical Assistance-only (TA)	1
By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	1
Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	100%

Addis Ababa University MER Indicators	2015
Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	97%
Numerator: Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	870
Denominator: Number of new ANC and L&D clients	900
By: Known positives at entry	161
By: Number of new positives identified	23
Sum of Positives Status disaggregates	184
Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	95%
Numerator: Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	175
Denominator: Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	184
Life-long ART (including Option B+)	175
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	105
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	70
Sum of Regimen Type disaggregates	175
Sum of New and Current disaggregates	175
Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	80%
Numerator: Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	500
Denominator: Total number of people in the target population	625
Age/sex: 20-24 Male	350
Age/sex: 20-24 Female	150
Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	80%
Numerator: Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	475
Denominator: Total number of people in the target population	594
Age/sex: 20-24 Male	370

Addis Ababa University MER Indicators	2015
Age/sex: 20-24 Female	105
Sum of Age/Sex disaggregates	475
Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth	70%
Numerator: Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	129
Denominator: Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	184
By infants who received a virologic test within 2 months of birth	67
By infants who received their first virologic HIV test between 2 and 12 months of age	62
Sum of Infant Age disaggregates	129
By infants with a positive virologic test result within 12 months of birth	
Number of adults and children receiving antiretroviral therapy (ART) [current] (DSD)	4252
Age/Sex: <1 Male	19
Age/Sex: 1-4 Male	56
Age/Sex: 5-14 Male	201
Age/Sex: 15+ Male	1378
Age/Sex: <1 Female	18
Age/Sex: 1-4 Female	55
Age/Sex: 5-14 Female	180
Age/Sex: 15+ Female	2345
Sum of age/sex disaggregates	4252
Aggregated Age/Sex: <1 Male	19
Aggregated Age/Sex: <1 Female	18
Aggregated Age/Sex: <15 Male	276
Aggregated Age/Sex: 15+ Male	1378
Aggregated Age/Sex: <15 Female	253
Aggregated Age/Sex: 15+ Female	4252
Sum of Aggregated Age/Sex disaggregates	6159
Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	78%
Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	193

Addis Ababa University MER Indicators	2015
Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	247
Number of adults and children newly enrolled on antiretroviral therapy (ART)	431
By Age/Sex: <1 Male	7
By Age/Sex: 1-4 Male	20
By Age/Sex: 5-9 Male	32
By Age/Sex: 10-14 Male	36
By Age/Sex: 15-19 Male	3
By Age/Sex: 20-24 Male	7
By Age/Sex: 25-49 Male	59
By Age/Sex: 50+ Male	5
By Age/Sex: <1 Female	6
By Age/Sex: 1-4 Female	19
By Age/Sex: 5-9 Female	32
By Age/Sex: 10-14 Female	31
By Age/Sex: 15-19 Female	20
By Age/Sex: 20-24 Female	40
By Age/Sex: 25-49 Female	106
By Age/Sex: 50+ Female	8
Sum of Age/Sex disaggregates	431
Aggregated Grouping by Age: <1 Male	7
Aggregated Grouping by Age: <1 Female	6
Aggregated Grouping by Age/Sex: <15 Male	95
Aggregated Grouping by Age/Sex: 15+ Male	74
Aggregated Grouping by Age/Sex: <15 Female	88
Aggregated Grouping by Age/Sex: 15+ Female	174
Sum of Aggregated Age/Sex disaggregates	431
Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	100%
Numerator: Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
Denominator: Total number of PEPFAR-supported ART sites	1

Addis Ababa University MER Indicators	2015
By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0
Sum of Numerator Site Support Type disaggregates	1
By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	1
By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	
Sum of Denominator Site Support Type disaggregates	1
Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	310
By Graduates: Doctors	310
Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	13%
Numerator: Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
Denominator: Total number of PEPFAR-supported HIV service delivery points	8
By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	7
By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	1
Service delivery type: Clinical	8

Hawassa University MER Indicators	2015
Number of PEPFAR-supported DSD and TA sites	3
By program area/support type: Treatment Direct Service Delivery (DSD)	1
By program area/support type: PMTCT Direct Service Delivery (DSD)	1
By program area/support type: General Population Prevention Direct Service Delivery (DSD)	3
By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	1
Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	100%

Hawassa University MER Indicators	2015
Numerator: Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1
Denominator: Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1
Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	89%
Numerator: Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2560
Denominator: Number of new ANC and L&D clients	2867
By: Known positives at entry	55
By: Number of new positives identified	11
Sum of Positives Status disaggregates	66
Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	88%
Numerator: Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	58
Denominator: Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	66
Life-long ART (including Option B+)	58
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	14
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	56
Sum of Regimen Type disaggregates	58
Sum of New and Current disaggregates	70
Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	70%
Numerator: Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350
Denominator: Total number of people in the target population	500
The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	252
Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth	71%
Numerator: Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	47

Hawassa University MER Indicators	2015
Denominator: Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	66
Number of adults and children receiving antiretroviral therapy (ART) [current] (DSD)	
Age/Sex: <1 Male	10
Age/Sex: 1-4 Male	30
Age/Sex: 5-14 Male	106
Age/Sex: 15+ Male	1254
Age/Sex: <1 Female	10
Age/Sex: 1-4 Female	29
Age/Sex: 5-14 Female	95
Age/Sex: 15+ Female	1962
Sum of age/sex disaggregates	3496
Aggregated Age/Sex: <1 Male	10
Aggregated Age/Sex: <1 Female	10
Aggregated Age/Sex: <15 Male	146
Aggregated Age/Sex: 15+ Male	1254
Aggregated Age/Sex: <15 Female	134
Aggregated Age/Sex: 15+ Female	1962
Sum of Aggregated Age/Sex disaggregates	3496
Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	
Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	326
Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	407
Number of adults and children newly enrolled on antiretroviral therapy (ART)	
By Age/Sex: <1 Male	3
By Age/Sex: 1-4 Male	10
By Age/Sex: 5-9 Male	17
By Age/Sex: 10-14 Male	18
By Age/Sex: 15-19 Male	8
By Age/Sex: 20-24 Male	17

Hawassa University MER Indicators	2015
By Age/Sex: 25-49 Male	150
By Age/Sex: 50+ Male	13
By Age/Sex: <1 Female	4
By Age/Sex: 1-4 Female	10
By Age/Sex: 5-9 Female	16
By Age/Sex: 10-14 Female	18
By Age/Sex: 15-19 Female	25
By Age/Sex: 20-24 Female	50
By Age/Sex: 25-49 Female	135
By Age/Sex: 50+ Female	10
Sum of Age/Sex disaggregates	504
Aggregated Grouping by Age: <1 Male	3
Aggregated Grouping by Age: <1 Female	4
Aggregated Grouping by Age/Sex: <15 Male	48
Aggregated Grouping by Age/Sex: 15+ Male	188
Aggregated Grouping by Age/Sex: <15 Female	48
Aggregated Grouping by Age/Sex: 15+ Female	220
Sum of Aggregated Age/Sex disaggregates	504
Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	100%
Numerator: Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
Denominator: Total number of PEPFAR-supported ART sites	1
By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	
Sum of Numerator Site Support Type disaggregates	1
By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	1
By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	
Sum of Denominator Site Support Type disaggregates	1
Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	200

Hawassa University MER Indicators	2015
By Graduates: Doctors	200
Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	33%
Numerator: Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
Denominator: Total number of PEPFAR-supported HIV service delivery points	3
By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	3
Service delivery type: Clinical	3

Jimma University MER Indicators	2015
Number of PEPFAR-supported DSD and TA sites	1
By program area/support type: Treatment Direct Service Delivery (DSD)	1
By program area/support type: PMTCT Direct Service Delivery (DSD)	1
By program area/support type: General Population Prevention Direct Service Delivery (DSD)	1
By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	1
Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	100%
Numerator: Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1
Denominator: Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1
Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	91%
Numerator: Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1176
Denominator: Number of new ANC and L&D clients	1294
By: Known positives at entry	14
By: Number of new positives identified	12
Sum of Positives Status disaggregates	26

Jimma University MER Indicators	2015
Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	96%
Numerator: Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	25
Denominator: Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	26
Life-long ART (including Option B+)	25
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	10
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15
Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	
Single-dose nevirapine (with or without tail)	0
Sum of Regimen Type disaggregates	25
Sum of New and Current disaggregates	25
Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	70%
Numerator: Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350
Denominator: Total number of people in the target population	500
Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth	73%
Numerator: Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	19
Denominator: Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	26
By infants who received a virologic test within 2 months of birth	10
By infants who received their first virologic HIV test between 2 and 12 months of age	
Sum of Infant Age disaggregates	10
By infants with a positive virologic test result within 12 months of birth	
Number of adults and children receiving antiretroviral therapy (ART) [current] (DSD)	3622
Age/Sex: <1 Male	14
Age/Sex: 1-4 Male	42
Age/Sex: 5-14 Male	152

Jimma University MER Indicators	2015
Age/Sex: 15+ Male	1224
Age/Sex: <1 Female	14
Age/Sex: 1-4 Female	42
Age/Sex: 5-14 Female	136
Age/Sex: 15+ Female	1998
Sum of age/sex disaggregates	3622
Aggregated Age/Sex: <1 Male	14
Aggregated Age/Sex: <1 Female	14
Aggregated Age/Sex: <15 Male	208
Aggregated Age/Sex: 15+ Male	1224
Aggregated Age/Sex: <15 Female	192
Aggregated Age/Sex: 15+ Female	1998
Sum of Aggregated Age/Sex disaggregates	0
Number of adults and children newly enrolled on antiretroviral therapy (ART)	599
By Age/Sex: <1 Male	5
By Age/Sex: 1-4 Male	13
By Age/Sex: 5-9 Male	21
By Age/Sex: 10-14 Male	24
By Age/Sex: 15-19 Male	7
By Age/Sex: 20-24 Male	15
By Age/Sex: 25-49 Male	133
By Age/Sex: 50+ Male	11
By Age/Sex: <1 Female	4
By Age/Sex: 1-4 Female	13
By Age/Sex: 5-9 Female	21
By Age/Sex: 10-14 Female	23
By Age/Sex: 15-19 Female	35
By Age/Sex: 20-24 Female	71
By Age/Sex: 25-49 Female	189
By Age/Sex: 50+ Female	14
Sum of Age/Sex disaggregates	599
Aggregated Grouping by Age: <1 Male	5

<u>Jimma University MER Indicators</u>	<u>2015</u>
Aggregated Grouping by Age: <1 Female	4
Aggregated Grouping by Age/Sex: <15 Male	63
Aggregated Grouping by Age/Sex: 15+ Male	166
Aggregated Grouping by Age/Sex: <15 Female	61
Aggregated Grouping by Age/Sex: 15+ Female	309
Sum of Aggregated Age/Sex disaggregates	0
Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	100%
Numerator: Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
Denominator: Total number of PEPFAR-supported ART sites	1
Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	172
By Graduates: Doctors	172
Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	100%
Numerator: Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
Denominator: Total number of PEPFAR-supported HIV service delivery points	1
By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	1
Service delivery type: Clinical	1

<u>Mekelle University MER Indicators</u>	<u>2015</u>
Number of PEPFAR-supported DSD and TA sites	11
By program area/support type: Treatment Direct Service Delivery (DSD)	1
By program area/support type: PMTCT Direct Service Delivery (DSD)	1
By program area/support type: General Population Prevention Direct Service Delivery (DSD)	6
By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	5
By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	4

Mekelle University MER Indicators	2015
Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	100%
Numerator: Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	1
Denominator: Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	1
Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95%
Numerator: Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1800
Denominator: Number of new ANC and L&D clients	1900
By: Known positives at entry	78
By: Number of new positives identified	6
Sum of Positives Status disaggregates	84
<p>This indicator measures the number of pregnant women with known HIV status, and includes women who were tested for HIV and received their results at ANC and labor and delivery, as well as those who were known HIV positive prior to pregnancy. The data is obtained from the registers at ANC and labor and delivery clinics. The target/number of new ANC and L&D clients was set based on previous performance and trends in service utilization.</p> <p>In FY 13, US implementing partners supported TAH to provide PMTCT services. In COP 14, this support is transitioning from CU-ICAP to Addis Ababa University. The USG PMTCT support at facility level is comprehensive, including HIV testing at ANC and L&D, provision of ARVs, integration of FP with HIV/AIDS services and support for mentor mothers.</p> <p>The target of 870 mothers with known HIV status and the number of ANC attendants at TAH was set based on performance trend of the supporting partners. The breakdown of known positives (60%) to new positives (40%) is based on previous year testing trends which show the majority of HIV+ women identified at ANC and L&D are known positives.</p>	
Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	90%
Numerator: Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	76
Denominator: Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	84
Life-long ART (including Option B+)	76
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	10
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	66
Sum of Regimen Type disaggregates	76

Mekelle University MER Indicators	2015
Sum of New and Current disaggregates	76
Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	70%
Numerator: Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350
Denominator: Total number of people in the target population	500
Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	
By key population type: Female sex workers (FSW)	10,000
Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	
Numerator: The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	102
Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth	70%
Numerator: Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	59
Denominator: Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	84
Number of adults and children receiving antiretroviral therapy (ART) [current] (DSD)	1365
Age/Sex: <1 Male	4
Age/Sex: 1-4 Male	12
Age/Sex: 5-14 Male	43
Age/Sex: 15+ Male	488
Age/Sex: <1 Female	4
Age/Sex: 1-4 Female	12
Age/Sex: 5-14 Female	38
Age/Sex: 15+ Female	764
Sum of age/sex disaggregates	1365
Aggregated Age/Sex: <1 Male	4
Aggregated Age/Sex: <1 Female	4
Aggregated Age/Sex: <15 Male	59
Aggregated Age/Sex: 15+ Male	488

Mekelle University MER Indicators	2015
Aggregated Age/Sex: <15 Female	54
Aggregated Age/Sex: 15+ Female	764
Sum of Aggregated Age/Sex disaggregates	1365
Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	
Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	386
Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	483
Number of adults and children newly enrolled on antiretroviral therapy (ART)	
By Age/Sex: <1 Male	1
By Age/Sex: 1-4 Male	4
By Age/Sex: 5-9 Male	6
By Age/Sex: 10-14 Male	7
By Age/Sex: 15-19 Male	2
By Age/Sex: 20-24 Male	5
By Age/Sex: 25-49 Male	46
By Age/Sex: 50+ Male	4
By Age/Sex: <1 Female	1
By Age/Sex: 1-4 Female	3
By Age/Sex: 5-9 Female	6
By Age/Sex: 10-14 Female	6
By Age/Sex: 15-19 Female	48
By Age/Sex: 20-24 Female	98
By Age/Sex: 25-49 Female	261
By Age/Sex: 50+ Female	19
Sum of Age/Sex disaggregates	517
Aggregated Grouping by Age: <1 Male	1
Aggregated Grouping by Age: <1 Female	1
Aggregated Grouping by Age/Sex: <15 Male	18
Aggregated Grouping by Age/Sex: 15+ Male	57
Aggregated Grouping by Age/Sex: <15 Female	16
Aggregated Grouping by Age/Sex: 15+ Female	426
Sum of Aggregated Age/Sex disaggregates	517

Mekelle University MER Indicators	2015
Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	100%
Numerator: Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
Denominator: Total number of PEPFAR-supported ART sites	1
By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1
By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	1
Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	150
By Graduates: Doctors	150
Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	11%
Numerator: Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
Denominator: Total number of PEPFAR-supported HIV service delivery points	9
By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1
By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	
Sum of Numerator Site Support Type disaggregates	1
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	9
By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	
Sum of Denominator Site Support Type disaggregates	9
Service delivery type: Community	
Service delivery type: Clinical	9
Sum of Service Delivery Type disaggregates	9

ii. Applicant Evaluation and Performance Measurement Plan:

Applicants must provide an overall jurisdiction- or community-specific evaluation and performance measurement plan that is consistent with the CDC strategy. At a minimum, the plan must:

- Describe how key program partners will participate in the evaluation and performance measurement planning processes.
- Describe the type of evaluations (i.e., process, outcome, or both) to be conducted.
- Describe key evaluation questions. Describe other information (e.g., performance measures to be developed by the applicant), as determined by the CDC program, that must be included.
- Describe potentially available data sources and feasibility of collecting appropriate evaluation and performance data.
- Describe how evaluation findings will be used for continuous program quality improvement.
- Describe how evaluation and performance measurement will contribute to developing an evidence base for programs that employ strategies lacking a strong effectiveness evidence base.

c. Organizational Capacity of Awardees to Execute the Approach:

Applicant must be able to manage program performance, evaluation, performance monitoring, financial reporting, and must have capacity to manage the required funds in accordance with the HHS Grants Policy Statement, which can be found at:

<http://www.hhs.gov/asfr/ogapa/aboutog/hhsgps107.pdf>

d. Work Plan:

Applicant must include a work plan that demonstrates how the outcomes, strategies, activities, timelines, and staffing will take place over the course of the award. Applicants must submit a detailed work plan for the first year of the project and a high level plan for the subsequent years.

e. CDC Monitoring and Accountability Approach

Monitoring activities include routine and ongoing communication between CDC and awardees, site visits, and awardee reporting (including work plans, performance, and financial reporting). HHS grants policy specifies the following HHS expectations for post-award monitoring for grants and cooperative agreements:

- Tracking awardees progress in achieving the desired outcomes.
- Insuring the adequacy of awardee systems that underlie and generate data reports.
- Creating an environment that fosters integrity in program performance and results.

Monitoring may also include the following activities:

- Ensuring that work plans are feasible based on the budget and consistent with the intent of the award.
- Ensuring that awardees are performing at a sufficient level to achieve objectives within stated timelines.
- Working with awardees on adjusting the work plan based on achievement of objectives and changing budgets.
- Monitoring performance measures (both programmatic and financial) to assure satisfactory performance levels.
- Other activities deemed necessary to monitor the award, if applicable.

These may include monitoring and reporting activities as outlined in HHS grants policy that assists grants management staff (e.g., grants management officers and specialists, and project officers) in the identification, notification, and management of high-risk grantees.

f. CDC Program Support to Awardees

In a cooperative agreement, CDC staff is substantially involved in the program activities, above and beyond routine grant monitoring. CDC activities for this program are as follows:

1. Organize an orientation meeting with the grantee for a briefing on applicable U.S. Government, HHS/CDC, and President's Emergency Plan for AIDS Relief (PEPFAR) expectations, regulations and key management requirements, as well as report formats and contents. The orientation could include meetings with staff from HHS agencies and the Office of the U.S. Global AIDS Coordinator (OGAC).
2. Review and make recommendations as necessary to the process used by the grantee to select key personnel and/or post-award subcontractors and/or sub grantees to be involved in the activities performed under this agreement, as part of the President's Emergency Plan for Relief (PEPFAR) Country Operational Plan (COP) review and approval process, managed by the OGAC.
3. Review and approve grantee's annual work plan and detailed budget, as part of the Emergency Plan for AIDS Relief Country Operational Plan review-and-approval process, managed by the Office of the U.S. Global AIDS Coordinator.
4. Review and approve the grantee's monitoring and evaluation plan, including for compliance with the strategic information guidance established by the OGAC.
5. Meet on a regular basis with the grantee to assess expenditures in relation to approved work plan and modify plans as necessary.
6. Meet on a quarterly basis with the grantee to assess quarterly technical and financial progress reports and modify plans as necessary.
7. Meet on an annual basis with the grantee to review annual progress report for each U.S. Government Fiscal Year, and to review annual work plans and budgets for the subsequent year, as part of the PEPFAR review and approval process for COPs, managed by OGAC.
8. Provide technical assistance, as mutually agreed upon, and revise annually during validation of the first and subsequent annual work plans. This could include expert technical assistance and targeted training activities in specialized areas, such as strategic information, project management, and confidential counseling and testing.
9. Provide in-country administrative support to help the grantee meet U.S. Government financial and reporting requirements approved by the Office of Management and Budget (OMB) under 0920-0428.
10. Collaborate with the grantee on designing and implementing the activities listed above, including, but not limited to: the provision of technical assistance to develop program activities, data management and analysis, quality assurance, the presentation and possibly publication of program results and findings, and the management and tracking of finances.

11. Provide technical assistance or advice on any data collections on 10 or more people that are planned or conducted by the awardee. All such data collections-- where CDC staff will be or are approving, directing, conducting, managing, or owning data-- must undergo OMB project determinations by CDC and may require OMB PRA clearance prior to the start of the project.
12. Provide consultation and scientific and technical assistance based on appropriate HHS/CDC and OGAC documents to promote the use of best practices known at the time.
13. Assist the grantee in developing and implementing quality-assurance criteria and procedures.
14. Facilitate in-country planning and review meetings for technical assistance activities.
15. Provide technical oversight for all activities under this award.
16. Conduct service delivery site visits through the Site Monitoring System (SMS) to monitor and evaluate site capacity to provide high-quality HIV/AIDS services in all program areas by assessing and scoring key program area elements of site performance and work with the grantee on identified gaps and continuous quality improvement.
17. Provide ethical reviews, as necessary, for evaluation activities, including from HHS/CDC headquarters. Evaluations can be process, outcome or impact.
 - A. Process Evaluation: measures how the intervention was delivered, what worked/did not, differences between the intended population and the population served, and access to the intervention.
 - B. Outcome Evaluation: determines effects of intervention in target population(s) (e.g., change in knowledge, attitudes, behavior, capacity, etc.).
 - C. Impact Evaluation: measures net effects of program and prove of causality
18. Supply the awardee with protocols for related evaluations.

B. Award Information

1. Type of Award:

Cooperative Agreement: CDC's substantial involvement in this program is indicated in the "CDC program Support to Awardees" section of this document.

2. Award Mechanism:

U2G-Global HIV/AIDS Non-Research Cooperative Agreements

3. Fiscal Year:

2015

4. Approximate Total Fiscal Year Funding:

\$4,000,000.00

5. Approximate Total Project Period Funding:

None

6. Total Project Period Length:
5 Years
7. Approximate Number of Awards:
4
8. Approximate Average Award:
\$675,000.00 for Hawassa University; \$775,000.00 for Jimma Universities; \$800,000.00 for Addis Ababa University; \$1,750,000.00 for Mekelle University
9. Floor of Individual Award Range:
None
10. Ceiling of Individual Award Range:
\$4,000,000.00 total Fiscal Year Funding: \$675,000.00 for Hawassa University \$775,000.00 for Jimma Universities \$800,000.00 for Addis Ababa University \$1,750,000.00 for Mekelle University (These amounts are subject to the availability of funds)
11. Anticipated Award Date:
April 1, 2015
12. Budget Period Length:
12 months Throughout the project period, CDC will continue the award based on the availability of funds, the evidence of satisfactory progress by the awardee (as documented in required reports), and the determination that continued funding is in the best interest of the federal government. The total number of years for which federal support has been approved (project period) will be shown in the "Notice of Award." This information does not constitute a commitment by the federal government to fund the entire period. The total project period comprises the initial competitive segment and any subsequent non-competitive continuation award(s). <i>Note: Applicants must only apply for the first budget period funding, taking into consideration the floor of the individual award range and the ceiling of the individual award range. The proposed budget for the first budget period must not exceed the ceiling of the individual award range. If a funding amount greater than the ceiling of the individual award range is requested, the application will be considered non-responsive and will not be entered into the review process.</i>
13. Funds Tracking:
Applicant is required to track fund by P-accounts/sub accounts for each project/cooperative agreement awarded.
14. Direct Assistance:
Direct assistance is not available through this FOA

15. Indirect Costs:

Indirect costs will not be reimbursed under grants to foreign organizations, international organizations, and foreign components of grants to domestic organizations (does not affect indirect cost reimbursement to the domestic entity for domestic activities). The CDC will not reimburse indirect costs unless the recipient has an indirect cost rate covering the applicable activities and period.

C. Eligibility Information

1. Eligible Applicants:

Eligible applicants that can apply for this FOA are listed below:

- Mekelle University
- Hawassa University
- Jimma University
- Addis Ababa University

2. Special Eligibility Requirements:

N/A

3. Justification for Less than Maximum Competition:

Eligibility for award is limited to the following four local universities:

- A. Mekelle University
- B. Hawassa University
- C. Jimma University
- D. Addis Ababa University

The four local universities, namely Addis Ababa, Hawassa, Jimma and Mekelle Universities, are public government educational institutions which are established by law and are mandated to support teaching hospitals and other health facilities under their authority. They are the only entities to lead and manage these health facilities. Each university provides services to more than 20,000 students, staff members, and the broader catchment area population of approximately 5,000,000. The university teaching hospitals are located in urban areas, have high patient loads, and serve as tertiary referral facility for large population coming from their respective regions and population of adjacent regions.

CDC-Ethiopia has supported the provision of STI/HIV and ART programs at these hospitals and university health facilities through cooperative agreements that have been in place since 2009. Continuity of services provided at these facilities is critical. These local universities have highly trained physicians and other health care providers that provide HIV services and can be potentially used for site level activities with minimal guidance and supervision. RHBs will also benefit from these groups of health professionals during training, supervision, mentoring and program evaluation.

Through their previous cooperative agreements with CDC-Ethiopia, these universities have built their administrative, programmatic and technical capacities to manage their programs and service delivery. In line with CDC-Ethiopia's transition strategy, which calls for the transition of activities from international partners to local partners, these universities will take over increased HIV prevention, ART program site level support, and in-service education from the departing international partner. This award will further strengthen their capacity to take on these activities.

Addis Ababa, Hawassa, Jimma and Mekelle Universities are public government universities which are established by law and are mandated to support the hospitals under their authority. They are the

entities that can lead and manage these hospitals as they are under the jurisdiction of these universities. Because of their mandate and authority to oversee the hospitals and the service deliberations in the hospitals, only these four universities are eligible for this award.

LEJ memo approved August 19, 2014

4. Other:

N/A

5. Cost Sharing or Matching:

Cost sharing or matching funds are not required for this program. Although there is no statutory match requirement for this FOA, leveraging other resources and related ongoing efforts to promote sustainability is strongly encouraged.

6. Maintenance of Effort:

Maintenance of Effort is not required for this program.

D. Application and Submission Information

Additional materials that may be helpful to applicants:

<http://www.cdc.gov/od/pgo/funding/docs/FinancialReferenceGuide.pdf>.

1. Required Registrations:

An organization must be registered at the three following locations before it can submit an application for funding at www.grants.gov.

- a. **Data Universal Numbering System:** All applicant organizations must obtain a Data Universal Numbering System (DUNS) number. A DUNS number is a unique nine-digit identification number provided by Dun & Bradstreet (D&B). It will be used as the Universal Identifier when applying for federal awards or cooperative agreements.

The applicant organization may request a DUNS number by telephone at 1-866-705-5711 (toll free) or internet at <http://fedgov.dnb.com/webform/displayHomePage.do>. The DUNS number will be provided at no charge.

If funds are awarded to an applicant organization that includes sub-awardees, those sub-awardees must provide their DUNS numbers before accepting any funds.

- b. **System for Award Management (SAM):** The SAM is the primary registrant database for the federal government and the repository into which an entity must submit information required to conduct business as an awardee. All applicant organizations must register with SAM, and will be assigned a SAM number. All information relevant to the SAM number must be current at all times during which the applicant has an application under consideration for funding by CDC. If an award is made, the SAM information must be maintained until a final financial report is submitted or the final payment is received, whichever is later. The SAM registration process can require 10 or more business days, and registration must be renewed annually. Additional information about registration procedures may be found at www.SAM.gov.
- c. **Grants.gov:** The first step in submitting an application online is registering your organization at www.grants.gov, the official HHS E-grant Web site. Registration information is located at the "Get Registered" option at www.grants.gov.

All applicant organizations must register at www.grants.gov. The one-time registration process usually takes not more than five days to complete. Applicants should start the registration process as early as possible.

Step	System	Requirements	Duration	Follow Up
1	Data Universal Number System (DUNS)	<ol style="list-style-type: none"> 1. Click on http://fedgov.dnb.com/webform 2. Select Begin DUNS search/request process 3. Select your country or territory and follow the instruction to obtain your DUNS 9-digit # 4. Request appropriate staff member(s) to obtain DUNS number, verify & update information under DUNS number 	1-2 Business Days	To confirm that you have been issued a new DUNS number check online at (http://fedgov.dnb.com/webform) or call 1-866-705-5711
2	System for Award Management (SAM) formerly Central Contractor Registration (CCR)	<ol style="list-style-type: none"> 1. Retrieve organizations DUNS number 2. Go to www.sam.gov and designate an E-Biz POC (note CCR username will not work in SAM and you will need to have an active SAM account before you can register on grants.gov) 	3-5 Business Days but up to 2 weeks and must be renewed once a year	For SAM Customer Service Contact www.fsd.gov/US Calls: 866-606-8220
3	Grants.gov	<ol style="list-style-type: none"> 1. Set up an individual account in Grants.gov using organization new DUNS number to become an authorized organization representative (AOR) 2. Once the account is set up the E-BIZ POC will be notified via email 3. Log into grants.gov using the password the E-BIZ POC received and create new password 4. This authorizes the AOR to submit applications on behalf of the organization 	Same day but can take 8 weeks to be fully registered and approved in the system (note, applicants MUST obtain a DUNS number and SAM account before applying on grants.gov)	Register early! Log into grants.gov and check AOR status until it shows you have been approved

2. Request Application Package:

Download the application package from www.grants.gov

3. Application Package

Applicants must download the SF-424 application package associated with this funding opportunity from www.grants.gov. If Internet access is not available, or if the online forms cannot be accessed, applicants may call the CDC PGO staff at 770-488-2700 or e-mail PGO PGOTIM@cdc.gov for assistance. Persons with hearing loss may access CDC telecommunications at TTY 1-888-32-6348.

4. Submission Dates and Times:

If the application is not submitted by the deadline published in the FOA, it will not be processed. PGO personnel will notify the applicant that their application did not meet the deadline. The applicant must receive pre-approval to submit a paper application (see Other Submission Requirements section for additional details). If the applicant is authorized to submit a paper application, it must be received by the deadline provided by PGO.

If Grants.gov cannot receive applications due to an emergency or other unanticipated event (and circumstances preclude advance notification of an extension), then applications must be submitted by the first business day on which government operations resume.

a. Letter of Intent (LOI) Deadline Date: (must be postmarked by): N/A

b. Application Deadline Date: October 28, 2014, 11:59 p.m. U.S. Eastern Standard Time, at www.grants.gov. Late submissions will be considered non-responsive.

If Grants.gov cannot receive applications due to an emergency or other unanticipated event (and circumstances preclude advance notification of an extension), then applications must be submitted by the first business day on which government operations resume.

5. CDC Assurances and Certifications:

All applicants are required to sign and submit CDC Assurances and Certifications documents that can be found on the CDC Web site: <http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm>

Applicants may follow either of the following processes:

- Applicants must name this file “Assurances and Certifications” and upload as a PDF on www.grants.gov.
- Complete the applicable assurances and certifications and submit them directly to CDC on an annual basis at <http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm>

Assurances and certifications submitted directly to CDC will be kept on file for 1 year and will apply to all applications submitted to CDC within one year of the submission date.

6. Content and Form of Application Submission:

Applicants are required to submit all of the documents outlined below as their application package on www.grants.gov.

7. Letter of Intent (LOI):

A letter of intent is not applicable to this funding opportunity announcement.

8. Table of Contents:

Provide a detailed table of contents for the entire submission package that includes all of the documents in the application and headings in the “Project Narrative” section. Name the file “Table of Contents” and upload it as a PDF file under “Other Attachment Forms” at www.grants.gov. There is no page limit. The table of contents is not included in the project narrative page limit

9. Project Abstract Summary:

(Maximum of 1 page)

A project abstract is included on the mandatory documents list and must be submitted at www.grants.gov. The project abstract must be a self-contained, brief summary of the proposed project including the purpose and outcomes. This summary must not include any proprietary or confidential information. Applicants must enter the summary in the “Project Abstract Summary” text box at www.grants.gov.

10. Project Narrative:

(Maximum of 18 pages, single spaced, Calibri 12 point, 1-inch margins, number all pages, content beyond 18 pages will not be reviewed).

The Project Narrative must include all of the bolded headings shown in this section. The Project Narrative must be succinct, self-explanatory, and in the order outlined in this section. It must address outcomes and activities to be conducted over the entire project period as identified in the CDC Project Description section.

Applicants must submit a Project Narrative with the application forms. Applicants must name this file “Project Narrative” and upload it at www.grants.gov.

- a. **Background:** Applicants should provide a description of relevant background information that includes the context of the problem (see CDC Background).
- b. **Approach**
Problem Statement: Applicants must describe the core information relative to the problem for the jurisdictions or populations they serve. The core information should help reviewers

understand how the applicant's response to the FOA will address the public health problem and support public health priorities. (See CDC Project Description).

Purpose: Applicants must describe specifically how their application will address the problem as described in the CDC Project Description.

Outcomes: Applicants must clearly identify the outcomes they expect to achieve by the end of the project period. Outcomes are the results that the program intends to achieve. All outcomes should indicate the intended direction of change (i.e., increase, decrease, maintain). See the program logic model in the Approach section of the CDC Project Description. In addition to the project period outcomes required by CDC, applicants should include any additional outcomes they anticipate.

Strategy and Activities: The applicant must provide a clear and concise description of the strategies and activities they will use to achieve the project period outcomes. Whenever possible, applicants should use evidence-based program strategies as identified by the Community Guide¹ (or similar reviews) and reference it explicitly as a source. Applicants may propose additional strategies and activities to achieve the outcomes. Applicants should select existing evidence-based strategies that meet their needs, or describe the rationale for developing and evaluating new strategies or practice-based innovations. (See CDC Project description: Strategies and Activities section).

1. **Collaborations:** Applicants must describe how they will collaborate with CDC funded programs as well as with organizations external of CDC.

Applicants must provide letters of support from the Regional Health Bureau, the Federal Ministry of Health, and the Federal Ministry of Education, name the files "Letters of Support," and upload as PDF files at www.grants.gov.

2. **Target Populations:** Applicants must describe the specific target population(s) to be addressed in their jurisdiction to allocate limited resources, target those at greatest health risk, and achieve the greatest health impact. Applicants should use data, including social determinants data, to identify communities within their jurisdictions or community served that are disproportionately affected by the public health problem, and plan activities to reduce or eliminate these disparities. Disparities by race, ethnicity, gender identity, sexual orientation, geography, socioeconomic status, disability status, primary language, health literacy, and other relevant dimensions (e.g., tribal communities) should be considered.

Inclusion: N/A

- c. **Applicant Evaluation and Performance Measurement Plan:** Applicants must provide an overall jurisdiction or community-specific evaluation and performance measurement plan that is consistent with the CDC Evaluation and Performance Measurement Strategy section of the CDC Project Description of this FOA. Data collected must be used for ongoing monitoring of the award to evaluate its effectiveness, and for continuous program improvement.

¹ <http://www.thecommunityguide.org/index.html>

The plan must:

- Describe how key program partners will be engaged in the evaluation and performance measurement planning processes.
- Describe the type of evaluations to be conducted (i.e. process and/or outcome).
- Describe key evaluation questions to be answered.
- Describe other information, as determined by the CDC program (e.g., performance measures to be developed by the applicant) that must be included.
- Describe potentially available data sources and feasibility of collecting appropriate evaluation and performance data.
- Describe how evaluation findings will be used for continuous program and quality improvement.
- Describe how evaluation and performance measurement will contribute to development of that evidence base, where program strategies are being employed that lack a strong evidence base of effectiveness.

Awardees will be required to submit a more detailed evaluation and performance measurement plan within the first six months of the project, as outlined in the reporting section of the FOA.

d. Organizational Capacity of Awardees to Execute the Approach:

Applicant must address the organizational capacity requirements as described in the CDC Project Description. Applicants must submit CVs/Resumes of Principle Investigator, HIV/AIDS Project Manager, and ART Program Coordinator as well as detailed job descriptions of Principle Investigator, HIV/AIDS Project Manager, ART Program Coordinator and HRH Coordinator. Applicants must also submit Organizational Charts. These items must be submitted as part of the appendix, clearly named "CVs/Resumes," "Job Descriptions," and "Organizational Charts," and uploaded as PDF files at www.grants.gov.

11. Work Plan:

(Included in the Project Narrative- 18 page limit)

Applicants must prepare a work plan consistent with the CDC Project Description Work Plan section. The work plan integrates and delineates more specifically how the awardee plans to carry out achieving the project period outcomes, strategies, and activities, evaluation and performance measurement, including key milestones.

12. Budget Narrative:

Applicants must submit an itemized, line-item budget and narrative with staffing breakdown (i.e., name, position title, annual salary, percentage of time and effort, and amount requested) and justification for all requested costs for the first budget period. Budgets must be consistent with the purpose, objectives of the Emergency Plan, and the program activities listed in this announcement. When developing the budget narrative, applicants should consider whether the proposed budget is reasonable and consistent with the purpose, outcomes and program strategy outlined in the project narrative. The budget must include:

- Salaries and wages
- Fringe benefits
- Consultant costs
- Equipment
- Supplies
- Travel
- Alterations and Renovations
- Other categories

- Contractual costs
- Total Direct costs
- Total Indirect costs

The detailed budget should identify costs associated with potential data collection activities from persons, personal records, or for laboratory specimen collection and testing that may result in a public report. For each of the potential data collection activities, also state the costs for any preparatory activities (e.g., protocol development, training, equipment, reagents, and site preparation).

When developing the budget narrative, applicants should consider whether the proposed budget is reasonable and consistent with the purpose, outcomes and program strategy outlined in the project narrative. All budget justification pages must be numbered.

For guidance on completing a detailed budget, see Budget Preparation Guidelines at: <http://www.cdc.gov/od/pgo/funding/budgetguide.htm>.

Applicants should name this “Budget Narrative” and upload as a PDF file to www.grants.gov.

If requesting indirect costs in the budget, a copy of the indirect cost rate agreement is required. If the indirect cost rate is a provisional rate, the agreement must have been made less than 12 months earlier. Applicants should name this file “Indirect Cost Rate” and upload to www.grants.gov.

If a funding amount greater than the ceiling of the individual award range is requested, the application will be considered non-responsive and will not be entered into the review process. The applicant will be notified that the application did not meet the eligibility requirements.

13. Tobacco and Nutrition Policies:

Awardees are encouraged to implement tobacco and nutrition policies.

Unless otherwise explicitly permitted under the terms of a specific CDC award, no funds associated with this FOA can be used to implement the optional policies, and no applicants will be evaluated or scored on whether they choose to participate in implementing these optional policies.

The CDC supports implementing evidence-based programs and policies to reduce tobacco use and secondhand smoke exposure, and to promote healthy nutrition. CDC encourages all awardees to implement the following optional recommended evidence-based tobacco and nutrition policies within their own organizations. This builds upon the current federal commitment to reduce exposure to secondhand smoke, which includes The Pro-Children Act, 20 U.S.C. 7181-7184, that prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, or early childhood development services are provided to children.

Tobacco Policies:

1. Tobacco-free indoors – no use of any tobacco products (including smokeless tobacco) or electronic cigarettes in any indoor facilities under the control of the awardee
2. Tobacco-free indoors and in adjacent outdoor areas – no use of any tobacco products or electronic cigarettes in any indoor facilities, within 50 feet of doorways and air intake ducts, and in courtyards under the control of the awardee
3. Tobacco-free campus – no use of any tobacco products or electronic cigarettes in any indoor facilities and anywhere on grounds or in outdoor space under the control of the awardee

Nutrition Policies:

1. Healthy food service guidelines should at a minimum, align with Health and Human Services and General Services Administration Health and Sustainability Guidelines for Federal Concessions and Vending Operations for cafeterias, snack bars, and vending machines in any facility under the control of the awardee and in accordance with contractual obligations for these services (http://www.gsa.gov/graphics/pbs/Guidelines_for_Federal_Concessions_and_Vending_Operations.pdf)
2. The following are resources for healthy eating and tobacco free workplaces:
<http://www.cdc.gov/nccdphp/dnpao/hwi/toolkits/tobacco/index.htm>
<http://www.thecommunityguide.org/tobacco/index.html>
<http://www.cdc.gov/chronicdisease/resources/guidelines/food-service-guidelines.htm>

14. Intergovernmental Review:

Executive Order 12372 does not apply to this program.

15. Funding Restrictions:

Restrictions that must be considered while planning the programs and writing the budget are:

- Awardees may not use funds for research.
- Awardees may not use funds for clinical care except as allowed by law.
- Awardees may only use funds for reasonable program purposes, including personnel, travel, supplies, and services (such as contractual).
- Generally, awardees may not use HHS/CDC/ATSDR funding for the purchase of furniture or equipment. Any such proposed spending must be clearly identified in the budget in accordance with CDC's budget guidelines.
- Pre-award costs may be allowable for successful applicants under this FOA prior to award.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC awardees.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- The applicant may contract with other organizations under this program; however the applicant must perform a substantial portion of the activities (including program management and operations, and delivery of prevention services for which funds are required.)
- All plans for data collection from persons or personal records and for laboratory specimen collection and testing that are expected to result in public reports will require protocols for technical review and review of institutional human subjects protection considerations by CDC. Funds for implementing these activities will be restricted until all necessary institutional protocol approvals have been obtained. Funds for preparatory activities (e.g., protocol development, training, equipment, reagents, and site preparation) may be provided prior to protocol approval. To facilitate the early availability of funding, the budget and narrative should clarify which activities are preparatory.
- Human subjects data collection funding restrictions which require submission of protocols will be

submitted within six months of notification of such requirement, but no later than the end of the first budget year. Requests for exceptions to these deadlines will need to be submitted in writing to the Grants Management Officer. All protocol approvals should be obtained no later than the end of the second budget period after the award or Continuation has been made, provided that the Grantee submits their protocol no later than the deadline.

- Needle Exchange – No funds made available under this award may be used for needle exchange programs.
- The recipient must use funds provided under the agreement for costs incurred in carrying out the purposes of the award which are reasonable, allocable, and allowable in accordance with applicable cost principles. Unallowable costs will be determined in accordance with the applicable cost principles.
 - “Reasonable” means the costs do not exceed those that would ordinarily be incurred by a prudent person in the conduct of normal business.
 - “Allocable” means the costs are necessary to the award.
 - “Allowable” means the costs are reasonable and allocable, and conform to any limitations set forth in the award.
- The recipient is encouraged to obtain the Grants Management Officer’s written determination in advance whenever the recipient is uncertain as to whether a cost will be allowable.
- The costs that are generally allowable in grants to domestic organizations are allowable to foreign institutions and international organizations, with the following exception: With the exception of the American University, Beirut and the World Health Organization, Indirect Costs will not be paid (either directly or through sub-award) to organizations located outside the territorial limits of the United States or to international organizations regardless of their location.
- All requests for funds contained in the budget, shall be stated in U.S. dollars. Once an award is made, CDC will not compensate foreign grantees for currency exchange fluctuations through the issuance of supplemental awards.
- Public Financial Management Assessment Clause: The Parties acknowledge that HHS/CDC has assessed the recipient’s systems required to manage the activities supported with US Government funds under this Agreement and that this Agreement is expressly conditioned upon that assessment, as well as any measures, mitigation or means by which the recipient has or will address the vulnerabilities or weaknesses, if any, found in that assessment. The recipient agrees to take the necessary action(s) to address the recommendations or requirements of the assessment as agreed separately in writing with HHS/CDC in accordance with an action plan to be jointly developed to address such recommendations or as otherwise contained in this agreement.
- It is the policy of HHS/CDC to seek to ensure that none of its funds are used, directly or indirectly, to provide support to individuals or entities designated for United Nations Security Council sanctions. In accordance with this policy, the applicant agrees to use reasonable efforts to ensure that none of the funds provided under this grant are used to provide support of individuals or entities designated for UN Security Council sanctions (compendium of Security Council Targeted Sanctions Lists at: http://www.un.org/sc/committees/list_compend.shtml). This provision must be included in all sub-agreements, including contracts and sub-awards, issued under this award.
- **Prohibition on Assistance to Drug Traffickers**
 - HHS/CDC reserves the right to terminate assistance to, or take other appropriate measures with respect to, any participant approved by HHS/CDC who is found to have been convicted of a narcotics offense or to have been engaged in drug trafficking as defined in 22 CFR Part 140.
 - The Applicant agrees not to disburse, or sign documents committing the Applicant to disburse funds to a sub-recipient designated by HHS/CDC ("Designated Sub-recipient") until advised by HHS/CDC that: (1) any United States Government review of the

Designated Sub-recipient and its key individuals has been completed; (2) any related certifications have been obtained; and (3) the assistance to the Designated Sub-recipient has been approved.

- The Applicant shall insert the following clause, or its substance, in its agreement with the Designated Sub-recipient:
 - The Applicant reserves the right to terminate this Agreement or take other appropriate measures if the [Sub-recipient] or a key individual of the [Sub-recipient] is found to have been convicted of a narcotic offense or to have been engaged in drug trafficking as defined in 22 CFR Part 140.
- **Conference Costs and Fees**

U.S. Government funds under this award must not be used to finance the travel, per diem, hotel expenses, meals, conference fees or other conference costs for any member of a foreign government's delegation to an international conference sponsored by a multilateral organization, as defined below, unless approved by the CDC in writing.

 - **Definitions:**
 - A foreign government delegation is appointed by the national government (including ministries and agencies but excluding local, state and provincial entities) to act on behalf of the appointing authority at the international conference. A conference participant is a delegate for the purposes of this provision, only when there is an appointment or designation that the individual is authorized to officially represent the government or agency. A delegate may be a private citizen.
 - An international conference is a meeting where there is an agenda, an organizational structure, and delegations from countries other than the conference location, in which country delegations participate through discussion, votes, etc.
 - A multilateral organization is an organization established by international agreement and whose governing body is composed principally of foreign governments or other multilateral organizations.
- **Using PEPFAR funds for Implementing Partners (IPs) and Partner Government Officials**

IPs are required to notify their Project Officer immediately upon abstract acceptance. Once accepted, IPs are required to submit a written justification to their Project Officer stating the rationale for seeking support to attend the conference. IPs with accepted oral posters or oral abstracts for presentations that give clear attribution to PEPFAR may be authorized to use PEPFAR funds for travel providing that funds are available for travel. Funds for travel must be drawn from an existing agreement with the IP and not from PEPFAR country program management and operations budget. IPs must obtain prior approval from their respective Project Officer for participation and on availability and use of funds.

PEPFAR partner government officials who wish to attend any large conference using PEPFAR funds must submit requests to the Project Officer, who will work with this PEPFAR Coordination office in-country, or to the designated PEPFAR Point of Contact in countries without Coordinators. Final decisions will be made in collaboration with the PEPFAR Deputy Principals and responses will be circulated to Post.

- **Attribution to PEPFAR**
 - All PEPFAR-related accepted abstracts presented by implementing partners during any conference (regardless of conference/meeting size) must be attributed to PEPFAR. All posters must include the PEPFAR logo as well as the following language: "This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through HHS/CDC under the terms of CDC-RFA-GH15-1523."
- **Abortion and Involuntary Sterilization Restrictions**

- Funds made available under this award must not be used to pay for the performance of involuntary sterilization as a method of family planning or to coerce or provide any financial incentive to any individual to practice sterilization.
- Prohibition on Abortion-Related Activities:
 - No funds made available under this award will be used to finance, support, or be attributed to the following activities: (i) procurement or distribution of equipment intended to be used for the purpose of inducing abortions as a method of family planning; (ii) special fees or incentives to any person to coerce or motivate them to have abortions; (iii) payments to persons to perform abortions or to solicit persons to undergo abortions; (iv) information, education, training, or communication programs that seek to promote abortion as a method of family planning; and (v) lobbying for or against abortion. The term “motivate”, as it relates to family planning assistance, must not be construed to prohibit the provision, consistent with local law, of information or counseling about all pregnancy options.
 - No funds made available under this award will be used to pay for any biomedical research which relates, in whole or in part, to methods of, or the performance of, abortions or involuntary sterilizations as a means of family planning. Epidemiologic or descriptive research to assess the incidence, extent or consequences of abortions is not precluded
- **Prostitution and Sex Trafficking**
 - A standard term and condition of award will be included in the final notice of award; all applicants will be subject to a term and condition that none of the funds made available under this award may be used to promote or advocate the legalization or practice of prostitution or sex trafficking. In addition, non-U.S. nongovernmental organizations will also be subject to an additional term and condition requiring the organization’s opposition to the practices of prostitution and sex trafficking.
- **Trafficking in Persons Provision**
 - No contractor or subrecipient under this Agreement that is a private entity may, during the period of time that the award is in effect:
 - engage in trafficking in persons, as defined in the Protocol to Prevent, Suppress, and Punish Trafficking in Persons, especially Women and Children, supplementing the UN Convention against Transnational Organized Crime;
 - procure any sex act on account of which anything of value is given to or received by any person; or
 - use forced labor in the performance of this award.
 - If HHS/CDC determines that there is a reasonable basis to believe that any private party contractor or subrecipient has violated paragraph 1 of this section or that an employee of the contractor or subrecipient has violated such a prohibition where that the employee’s conduct is associated with the performance of this award or may be imputed to the contractor or subrecipient, HHS/CDC may, without penalty, (i) require the Grantee to terminate immediately the contract or subaward in question or (ii) unilaterally terminate this Agreement in accordance with the termination provision.
 - For purposes of this provision, “employee” means an individual who is engaged in the performance in any part of the Project as a direct employee, consultant, or volunteer of any private party contractor or subrecipient.
 - The Applicant must include in all subagreements, including subawards and contracts, a provision prohibiting the conduct described in subsection a by private party subrecipients, contractors, or any of their employees
- **Requirements for Voluntary Family Planning Projects**

- A family planning project must comply with the requirements of this paragraph.
- A project is a discrete activity through which a governmental or nongovernmental organization or Public International Organization (PIO) provides family planning services to people and for which funds obligated under this award, or goods or services financed with such funds, are provided under this award, except funds solely for the participation of personnel in short-term, widely attended training conferences or programs.
- (3) Service providers and referral agents in the project must not implement or be subject to quotas or other numerical targets of total number of births, number of family planning acceptors, or acceptors of a particular method of family planning. Quantitative estimates or indicators of the number of births, acceptors, and acceptors of a particular method that are used for the purpose of budgeting, planning, or reporting with respect to the project are not quotas or targets under this paragraph, unless service providers or referral agents in the project are required to achieve the estimates or indicators.
- (4) The project must not include the payment of incentives, bribes, gratuities or financial rewards to (i) any individual in exchange for becoming a family planning acceptor, or (ii) any personnel performing functions under the project for achieving a numerical quota or target of total number of births, number of family planning acceptors, or acceptors of a particular method of contraception. This restriction applies to salaries or payments paid or made to personnel performing functions under the project if the amount of the salary or payment increases or decreases based on a predetermined number of births, number of family planning acceptors, or number of acceptors of a particular method of contraception that the personnel affect or achieve.
- (5) A person must not be denied any right or benefit, including the right of access to participate in any program of general welfare or health care, based on the person's decision not to accept family planning services offered by the project.
- The project must provide family planning acceptors comprehensible information about the health benefits and risks of the method chosen, including those conditions that might render the use of the method inadvisable and those adverse side effects known to be consequent to the use of the method. This requirement may be satisfied by providing information in accordance with the medical practices and standards and health conditions in the country where the project is conducted through counseling, brochures, posters, or package inserts.
 - The recipient must notify CDC when it learns about an alleged violation in the requirements for voluntary family planning projects described in paragraphs (3), (4), or (5), above.
 - The recipient must investigate and take appropriate corrective action, if necessary, when it learns about an alleged violation and must notify CDC about violations in a project affecting a number of people over a period of time that indicate there is a systemic problem in the project.
 - The recipient must provide CDC such additional information about violations as CDC may request.
- **Investment Promotion**
 - No funds or other support provided hereunder may be used to provide a financial incentive to a business enterprise currently located in the United States for the purpose of inducing such an enterprise to relocate outside the United States if such incentive or inducement is likely to reduce the number of employees of such business enterprise in the United States because United States production is being replaced by such enterprise outside the United States.
 - In the event the Applicant requires clarification from HHS/CDC as to whether the activity

would be consistent with the limitation set forth above, the Applicant must notify HHS/CDC and provide a detailed description of the proposed activity. The Applicant must not proceed with the activity until advised by HHS/CDC that it may do so.

- The Applicant must ensure that its employees and subcontractors and sub-recipients providing investment promotion services hereunder are made aware of the restrictions set forth in this clause and must include this clause in all subcontracts and other sub-agreements entered into hereunder.
- **Worker's Rights**
 - No funds or other support provided hereunder may be used for any activity that contributes to the violation of internationally recognized workers' rights of workers in the recipient country.
 - In the event the Applicant is requested or wishes to provide assistance in areas that involve workers' rights or the Applicant requires clarification from HHS/CDC as to whether the activity would be consistent with the limitation set forth above, the Applicant must notify HHS/CDC and provide a detailed description of the proposed activity. The Applicant must not proceed with the activity until advised by HHS/CDC that it may do so.
 - The Applicant must ensure that all employees and subcontractors and sub-recipients providing employment-related services hereunder are made aware of the restrictions set forth in this clause and must include this clause in all subcontracts and other sub-agreements entered into hereunder.
 - The term "internationally recognized worker rights" includes-- the right of association; the right to organize and bargain collectively; a prohibition on the use of any form of forced or compulsory labor; a minimum age for the employment of children, and a prohibition on the worst forms of child labor; and acceptable conditions of work with respect to minimum wages, hours of work, and occupational safety and health.
 - The term "worst forms of child labor" means-- all forms of slavery or practices similar to slavery, such as the sale or trafficking of children, debt bondage and serfdom, or forced or compulsory labor, including forced or compulsory recruitment of children for use in armed conflict; the use, procuring, or offering of a child for prostitution, for the production of pornography or for pornographic purposes; the use, procuring, or offering of a child for illicit activities in particular for the production and trafficking of drugs; and work which, by its nature or the circumstances in which it is carried out, is likely to harm the health, safety, or morals of children, as determined by the laws, regulations, or competent authority of the country.
- **Contract Insurance Requirement**

To the extent that a host government partner enters into contracts expressly approved by the U.S. government, the host country government partner shall ensure that its contractors or subcontractors (a) provide, before commencing performance under any contracts or subcontracts funded under this agreement, such workers' compensation insurance or security as required by HHS/CDC and (b) continue to maintain such insurance until performance is completed. The host country government partner shall insert, in all contracts and subcontracts under this agreement, a clause similar to this clause (including this sentence) imposing upon those contractors and subcontractors the obligation to obtain workers' compensation insurance or security as required by HHS/CDC.
- No funds or other support provided under the award may be used for support to any military or paramilitary force or activity, or for support to any police, prison authority, or other security or law enforcement forces without the prior written consent of HHS/CDC.
- **Conscience Clause**

An organization, including a faith-based organization, that is otherwise eligible to receive funds

under this agreement for HIV/AIDS prevention, treatment, or care—

- Shall not be required, as a condition of receiving such assistance—
- To endorse or utilize a multisectoral or comprehensive approach to combating HIV/AIDS; or
- To endorse, utilize, make a referral to, become integrated with, or otherwise participate in any program or activity to which the organization has a religious or moral objection; and
- Shall not be discriminated against in the solicitation or issuance of grants, contracts, or cooperative agreements for refusing to meet any requirement described above.

- **Medically Accurate Information About Condoms**

Information provided about the use of condoms as part of projects or activities funded under the award must be medically accurate and must include the public health benefits and failure rates of such use.

- **Financing of Terrorism**

Consistent with numerous United Nations Security Council resolutions, including UNSCR 1267 (1999) ([http://www.undemocracy.com/S-RES-1269\(1999\).pdf](http://www.undemocracy.com/S-RES-1269(1999).pdf)), UNSCR 1368 (2001) ([http://www.undemocracy.com/S-RES-1368\(2001\).pdf](http://www.undemocracy.com/S-RES-1368(2001).pdf)), UNSCR 1373 (2001) ([http://www.undemocracy.com/S-RES-1373\(2001\).pdf](http://www.undemocracy.com/S-RES-1373(2001).pdf)), and UNSCR 1989 (2011), both HHS/CDC and the Applicant are firmly committed to the international fight against terrorism, and in particular, against the financing of terrorism. It is the policy of HHS/CDC to seek to ensure that none of its funds are used, directly or indirectly, to provide support to individuals or entities associated with terrorism. In accordance with this policy, the Applicant agrees to use reasonable efforts to ensure that none of the HHS/CDC funds provided under this Agreement are used to provide support to individuals or entities associated with terrorism, including those identified on the U.S. Department of Treasury Office of Foreign Assets Control Specially Designated Nationals List. This provision must be included in all subagreements, including contracts and subawards, issued under this award.

- **Source and Nationality and Other Procurement Restrictions**

- Disbursements will be used exclusively to finance the costs of goods and services required for this Agreement [in accordance with 22 CFR 228, and] having their source and nationality in countries [included in Geographic Code [937 or 935]] OR [identified in subsection 6 below], except as HHS/CDC may otherwise agree in writing and as follows:
 - Ocean transportation costs must be financed under the Agreement only on vessels under flag registry of [countries included in Code 935] OR [the following countries: LIST. Also see subsection 7 below on use of U.S.-flag vessels.
 - Any motor vehicles financed under the Agreement will be of United States manufacture, except as HHS/CDC may otherwise agree in writing.
- The nationality of the contractor providing ocean and air shipping services will be deemed to be the ocean vessel's or aircraft's country of registry at the time of shipment.
- Provisions concerning restricted and ineligible goods and services may be provided in subsequent written communications between the parties. Special procurement rules apply to agricultural commodities, pharmaceuticals, pesticides, and fertilizer, none of which may be procured without advance written consent of HHS/CDC.
- Transportation by air of property or persons financed under this agreement will be on carriers holding United States certification, to the extent service by such carriers is available under the Fly America Act. This requirement may be further described by HHS/CDC in subsequent written communications between the parties.
- Eligibility Date. No goods or services may be financed under the Agreement which are procured pursuant to orders or contracts firmly placed or entered into prior to the date of this Agreement, except as the Parties may otherwise agree in writing.

- Eligible countries for procurement: HHS/CDC to identify for specific agreement.
- Transportation
 - In addition to the requirements in subsection 1 above, costs of ocean or air transportation and related delivery services may not be financed under this Agreement, if the costs are for transportation under an ocean vessel or air charter which has not received prior HHS/CDC approval.
 - Unless HHS/CDC determines that privately owned U.S. -flag commercial ocean vessels are not available at fair and reasonable rates for such vessels, or otherwise agrees in writing:
 - At least fifty percent (50%) of the gross tonnage of all goods (computed separately for dry bulk carriers, dry cargo liners and tankers) financed by HHS/CDC which may be transported on ocean vessels will be transported on privately owned U.S.-flag commercial vessels; and
 - At least fifty percent (50%) of the gross freight revenue generated by all shipments financed by HHS/CDC and transported to the territory of the Grantee on dry cargo liners shall be paid to or for the benefit of privately owned U.S.-flag commercial vessels. Compliance with the requirements of (1) and (2) of this subsection must be achieved with respect to both any cargo transported from U.S. ports and any cargo transported from non-U.S. ports, computed separately.
- **Environmental Impact Statement**

HHS/CDC and the Applicant agree to implement the Project in conformance with the regulatory and legal requirements of the Partner Country's environmental legislation and HHS/CDC's environmental policies.

 - The Applicant is required to create and follow an environmental mitigation plan and report (EMPR) for each thematic area covered by this agreement. The EMPR shall include the following:
 - Coversheet;
 - Narrative with project specific information, including level of effort;
 - Annexes:
 - Environmental Screening Form (Table 1);
 - Identification of Mitigation Plan (Table 2);
 - Environmental Monitoring and Tracking Table (Table 3);
 - Photos and Maps, as appropriate.
 - The EMPR will capture potential environmental impacts and also inform whether a supplemental Initial Environmental Examination (IEE) is required and should be completed and submitted to HHS/CDC.
- **Branding**

All PEPFAR-funded programs or activities must adhere to PEPFAR branding guidance, which includes guidance on the use of the PEPFAR logo and/or written attribution to PEPFAR. PEPFAR branding guidance can be found at <http://www.pepfar.gov/reports/guidance/branding/index.htm>
- **The 8% Rule**

The President's Emergency Plan for AIDS Relief (PEPFAR) seeks to promote sustainability for programs through the development, use, and strengthening of local partnerships. The diversification of partners also ensures additional robust capacity at the local and national levels.

To achieve this goal, the Office of the Global AIDS Coordinator (OGAC) establishes an annual funding guideline for grants and cooperative agreement planning. Within each annual PEPFAR country budget, OGAC establishes a limit for the total amount of U.S. Government funding for

HIV/AIDS activities provided to a single partner organization under all grant and cooperative agreements for that country. For U.S. Government fiscal year (FY) 2015, the limit is no more than 8 percent of the country's FY 2015 PEPFAR program funding (excluding U.S. Government management and staffing costs), or \$2 million, whichever is greater. The total amount of funding to a partner organization includes any PEPFAR funding provided to the partner, whether directly as prime partner or indirectly as sub-grantee. In addition, subject to the exclusion for umbrella awards and drug/commodity costs discussed below, all funds provided to a prime partner, even if passed through to sub-partners, are applicable to the limit. PEPFAR funds provided to an organization under contracts are not applied to the 8 percent/\$2 million single partner ceiling. Single-partner funding limits will be determined by PEPFAR after the submission of the COP(s). Exclusions from the 8 percent/\$2 million single-partner ceiling are made for (a) umbrella awards, (b) commodity/drug costs, and (c) Government Ministries and parastatal organizations. A parastatal organization is defined as a fully or partially state-owned corporation or government agency. For umbrella awards, grants officers will determine whether an award is an umbrella for purposes of exception from the cap on an award-by-award basis. Grants or cooperative agreements in which the primary objective is for the organization to make sub-awards and at least 75 percent of the grant is used for sub-awards, with the remainder of the grant used for administrative expenses and technical assistance to sub-grantees, will be considered umbrella awards and, therefore, exempted from the cap. Agreements that merely include sub-grants as an activity in implementation of the award but do not meet these criteria will not be considered umbrella awards, and the full amount of the award will count against the cap. All commodity/drug costs will be excluded from partners' funding for the purpose of the cap. The remaining portion of awards, including all overhead/management costs, will be counted against the cap.

Applicants should be aware that evaluation of proposals will include an assessment of grant/cooperative agreement award amounts applicable to the applicant by U.S. Government fiscal year in the relevant country. An applicant whose grants or cooperative agreements have already met or exceeded the maximum, annual single-partner limit may submit an application in response to this FOA. However, applicants whose total PEPFAR funding for this country in a U.S. Government fiscal year exceeds the 8 percent/\$2 million single partner ceiling at the time of award decision will be ineligible to receive an award under this FOA unless the U.S. Global AIDS Coordinator approves an exception to the cap. Applicants must provide in their proposals the dollar value by U.S. Government fiscal year of current grants and cooperative agreements (including sub-grants and sub-agreements) financed by the Emergency Plan, which are for programs in the country(ies) covered by this FOA. For example, the proposal should state that the applicant has \$_____ in FY 2015 grants and cooperative agreements (for as many fiscal years as applicable) in Ethiopia. For additional information concerning this FOA, please contact the Grants Management Officer for this FOA.

16. Other Submission Requirements:

- a. **Electronic Submission:** Applications must be submitted electronically at www.grants.gov. The application package can be downloaded from www.grants.gov. Applicants can complete the application package off-line, and then submit the application by uploading it at www.grants.gov website. All application attachments must be submitted using a PDF file format. Directions for creating PDF files can be found at www.grants.gov. File formats other than PDF may not be readable by PGO TIMS staff.

Applications must be submitted electronically by using the forms and instructions posted for this funding opportunity on www.grants.gov.

If Internet access is not available or if the forms cannot be accessed on-line, applicants may contact the PGO TIMS staff at 770-488-2700 or by e-mail at pgotim@cdc.gov, Monday through Friday, 7:30 am–4:30 pm Eastern Standard Time (EST), except federal government holidays. Electronic applications will be considered successful if they are available to PGO TIMS staff for processing from www.grants.gov on the deadline date.

Do not use “special characters (i.e. %, &, * etc.) on the cover page of your application (form SF 424 – Application for Federal Assistance) as special characters are not recognized by the electronic system. Use of special characters may result in your application being rejected. When copy/paste is used on application documents, the grantee should ensure that text only is pasted. When extra, blank spaces at the end of the original are pasted into the new document it causes the system to reject the document.

- b. Tracking Number:** Applications submitted through www.grants.gov, are time/date stamped electronically and assigned a tracking number. The Authorized Organization Representative (AOR) will receive an email notice of receipt when www.grants.gov receives the application. The tracking number serves to document that the application has been submitted and initiates the electronic validation process before the application is made available to CDC.
- c. Validation Process:** Application submission is not concluded until successful completion of the validation process. After submission of the application package, applicants will receive a “submission receipt” email generated by www.grants.gov. A second email message to applicants will then be generated by www.grants.gov that will either validate or reject the submitted application package. This validation process may take as long as two (2) business days. Applicants are strongly encouraged to check the status of their application to ensure submission of their package is complete and no submission errors have occurred. Applicants also are strongly encouraged to allocate ample time for filing to guarantee that their application can be submitted and validated by the deadline published in the FOA. Non-validated applications will not be accepted after the published application deadline date.

If you do not receive a “validation” e-mail within two business days of application submission, please contact www.grants.gov. For instructions on how to track your application, refer to the e-mail message generated at the time of application submission or the Application User Guide, Version 3.0, page 57.

- d. Technical Difficulties:** If the applicant encounters technical difficulties with www.grants.gov, the applicant should contact www.grants.gov Customer Service. The www.grants.gov Contact Center is available 24 hours a day, 7 days a week, with the exception of Federal Holidays. You can reach the www.grants.gov Contact Center at 1-800-518-4726 or by email at support@www.grants.gov. Submissions sent by email, fax, CD’s or thumb drives of applications will not be accepted. Please note that www.grants.gov is managed by HHS.

If Grants.gov is inoperable and cannot receive applications due to an emergency or other unanticipated event that results in the suspension of government operations (and circumstances preclude advance notification of an extension), then applications must be submitted by the first business day on which government operations resume.

- e. Paper Submission:** If technical difficulties are encountered at www.grants.gov, applicants should call the www.grants.gov Contact Center at 1-800-518-4726 or e-mail them at

support@www.grants.gov for assistance. After consulting with the Contact Center, if the technical difficulties remain unresolved and electronic submission is not possible, applicants may e-mail or call CDC GMO/GMS, before the deadline, and request permission to submit a paper application. Such requests are handled on a case-by-case basis.

An applicant's request for permission to submit a paper application must include the following three items:

1. Include the www.grants.gov case number assigned to the inquiry;
2. Describe the difficulties that prevent electronic submission and the efforts taken with the www.grants.gov Contact Center to submit electronically; and
3. Be received via e-mail to the GMS listed below at least three calendar days before the application deadline. Paper applications submitted without prior approval will not be considered. If a paper application is authorized, PGO will advise the applicant of specific instructions for submitting the application (e.g., original and two hard copies of the application by U.S. mail or express delivery service).

E. Application Review Information

1. Review and Selection Process:

Applications will be reviewed in three phases

a. Phase I Review:

All applications will be reviewed initially for completeness by the CDC's Procurement and Grants Office (PGO) staff and will be reviewed jointly for eligibility by the CDC Division of Global HIV/AIDS and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance to Phase II review. Applicants will be notified that the application did not meet eligibility and/or published submission requirements.

b. Phase II Review:

An objective review panel will evaluate complete, eligible applications in accordance with the "Criteria" section of the FOA.

Ability to Carry Out the Proposal (25 points):

Does the applicant demonstrate the local experience in Ethiopia and institutional capacity (both management and technical) to achieve the goals of the FOA with documented good governance practices? (10 points)

Does the applicant have the ability to coordinate and collaborate with existing Emergency Plan partners and other donors, including the Global Fund and other U.S. Government Departments and agencies involved in implementing the President's Emergency Plan, including the U.S. Agency for International Development? (5 points)

Is there evidence of current or past efforts to enhance HIV prevention, care and treatment in country? Where applicable, does the applicant have the capacity to reach rural and other underserved populations in Ethiopia? Where applicable, does the organization have the ability to target audiences that frequently fall outside the reach of the traditional media, and in local languages? To what extent does the applicant provide letters of support? (10 points)

Technical and Programmatic Approach (20 points):

Does the application include an overall strategy, including measurable time lines, clear monitoring and evaluation procedures, and specific activities for meeting the proposed outcomes? (5 points)

Does the applicant display knowledge of the strategy, principles and goals of the President's

Emergency Plan, and are the proposed activities consistent with and pertinent to that strategy and those principles and goals? (5 points)

Does the applicant describe activities that are evidence based, realistic, achievable, measurable and culturally appropriate to achieve the goals of the President's Emergency Plan? (5 points)

Does the application propose to build on and complement the current national response with evidence-based strategies designed to meet the goals of the President's Emergency Plan? Does the application include reasonable estimates of output targets? (For example, the numbers of sites to be supported, number of clients the program will reach.) To what extent does the applicant propose to work with other organizations? (5 points)

The reviewers will assess the feasibility of the applicant's plan to meet the outcomes, congruency of application with the logic model, whether the proposed use of funds is efficient, and the extent to which the specific methods described are appropriate for the local culture.

Understanding of the Problem (10 points):

Does the applicant demonstrate a clear and concise understanding of the current national HIV/AIDS response and the cultural and political context relevant to the programmatic areas targeted? (5 points)

Does the applicant display an understanding of the Five-Year Strategy and goals of the President's Emergency Plan? To what extent does the applicant justify the need for this FOA within the target community? (5 points)

Capacity Building (10 points):

Does the applicant have a proven track record of building the capacity of indigenous organizations and individuals? Does the applicant have relevant experience in using participatory methods, and approaches, in project planning and implementation? Does the applicant describe an adequate and measurable plan to progressively strengthen the capacity of local organizations and target beneficiaries to respond to the epidemic? If not a local indigenous organization, does the applicant articulate a clear exit strategy which will maximize the sustainability of project results in the intervention communities? Does the capacity building plan clearly describe how it will contribute to a) improved quality and geographic coverage of service delivery to achieve the "3,12,12²" targets of the President's Emergency Plan, and b) (if not a local indigenous organization) an evolving role of the prime beneficiary with transfer of critical technical and management competence to local organizations/sites in support of a decentralized response?

Monitoring and Evaluation (15 points):

Does the applicant demonstrate the local experience and capability to implement performance monitoring and rigorous evaluation of the project? Does the evaluation and performance measurement plan appropriately address the components specified in this announcement (i.e. key evaluation questions, types of evaluations to be conducted, performance measures (i.e., indicators), how often performance measures must be reported, how evaluation and performance measurement will track how target populations are affected by FOA strategies, how evaluation findings and performance measures will be used and yield findings to demonstrate the value of the FOA, and how results will be disseminated. Does the applicant describe a performance monitoring

² The President's Emergency Plan for AIDS Relief (PEPFAR) has called for immediate, comprehensive and evidence based action to turn the tide of global HIV/AIDS. As called for by the PEPFAR Reauthorization Act of 2008, initiative goals over the period of 2009 through 2013 are to treat at least three million HIV infected people with effective combination anti-retroviral therapy (ART); care for twelve million HIV infected and affected persons, including five million orphans and vulnerable children; and prevent twelve million infections worldwide.

system used to routinely review data and adjust program activities accordingly? Is the evaluation and performance plan consistent with the principles of the "Three Ones"³? Are there performance measures (i.e. indicators) developed for each program milestone, and incorporated into the financial and programmatic reports? Are the indicators consistent with the President's Emergency Plan Indicator Guide and other HHS/CDC requirements? Does the applicant demonstrate a system able to generate financial and program reports to show disbursement of funds, and progress towards achieving the numerical objectives of the President's Emergency Plan and HHS/CDC priorities?

Personnel (10 points):

Does the organization employ staff fluent in local languages who will work on this project? Are the staff roles clearly defined? As described, will the staff be sufficient to meet the goals of the proposed project? If not an indigenous organization, does the staff plan adequately involve local individuals and organizations? Are staff involved in this project qualified to perform the tasks described? Curricula vitae provided should include information that they are qualified in the following: management of HIV/AIDS prevention activities, especially confidential, voluntary counseling and testing; and the development of capacity building among and collaboration between Governmental and non-governmental partners.

Administration and Management (10 points):

Does the applicant provide a clear plan for the administration and management of the proposed activities, and to manage the resources of the program, prepare reports, monitor and evaluate activities, audit expenditures and produce collect and analyze performance data? Is the management structure for the project sufficient to ensure speedy implementation of the project? If appropriate, does the applicant have a proven track record in managing large budgets; running transparent and competitive procurement processes; supervising consultants and contractors; using subgrants or other systems of sharing resources with community based organizations, faith based organizations or smaller non-governmental organizations; and where appropriate providing technical assistance in health system strengthening activities such as laboratory or pharmacy management? (10 points).

The grantee must demonstrate an ability to submit quarterly reports in a timely manner to the HHS/CDC office.

Budget (Reviewed Not Scored)

Is the itemized budget for conducting the project, along with justification, reasonable and consistent with stated objectives and planned program activities? Is the budget itemized, well justified and consistent with the goals of the President's Emergency Plan for AIDS Relief? If applicable, are there reasonable costs per client reached for both year one and later years of the project?

Not more than thirty days after the Phase II review is completed, applicants will be notified electronically if their application does not meet eligibility or published submission requirements.

³ The Emergency Plan supports the multi-sectoral national responses in host nations, adapting U.S. support to the individual needs and challenges of each nation where the Emergency Plan is at work. Countries and communities are at different stages of HIV/AIDS response and have unique drivers of HIV, distinctive social and cultural patterns (particularly with regard to the status of women), and different political and economic conditions. Effective interventions must be informed by local circumstances and coordinated with local efforts. In April 2004, OGAC, working with UNAIDS, the World Bank, and the U.K. Department for International Development (DfID), organized and co-chaired a major international conference in Washington for major donors and national partners to consider and adopt key principles for supporting coordinated country-driven action against HIV/AIDS. These principles became known as the "Three Ones": - one national plan, one national coordinating authority, and one national monitoring and evaluation system in each of the host countries in which organizations work. Rather than mandating that all contributors do the same things in the same ways, the Three Ones facilitate complementary and efficient action in support of host nations.

c. Phase III Review:
N/A
2. Anticipated Announcement and Award Dates:
The anticipated announcement date is February 2015. The award date will be April 1, 2015.

F. Award Administration Information

1. Award Notices:

Awardees will receive an electronic copy of the Notice of Award (NoA) from the CDC PGO. The NoA shall be the only binding, authorizing document between the awardee and CDC. The NoA will be signed by an authorized GMO and emailed to the awardee program director.

Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration and Federal Funding Accountability And Transparency Act Of 2006 (FFATA) requirements.

Unsuccessful applicants will receive notification of the results of the application review by email with delivery receipt or by mail.

2. Administrative and National Policy Requirements:

Awardees must comply with the administrative requirements outlined in 45 Code of Federal Regulations (CFR) Part 74 or Part 92, as appropriate. To view brief descriptions of relevant provisions visit the CDC website at: http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm

The following administrative requirements apply to this project:

Generally applicable administrative requirements (ARs):

- AR-9: Paperwork Reduction Act
- AR-10: Smoke-Free Workplace
- AR-11: Healthy People 2020
- AR-12: Lobbying Restrictions
- AR-13: Prohibition on Use of CDC Funds for Certain Gun Control Activities
- AR-14: Accounting System Requirements
- AR-16: Security Clearance Requirement
- AR-21: Small, Minority, And Women-owned Business
- AR-24: Health Insurance Portability and Accountability Act
- AR-25: Release and Sharing of Data
- AR-26: National Historic Preservation Act of 1966
- AR-29: Compliance with EO13513, "Federal Leadership on Reducing Text Messaging while Driving," October 1, 2009
- AR-30: Compliance with Section 508 of the Rehabilitation Act of 1973
- AR- 32: Executive Order 131410: Promoting Quality and Efficient Health Care in Federal Government (If applicable applicants should be aware of the program's current business needs and how they align with nationally adopted Public Health Information Network (PHIN) standards, services, practices, and policies when implementing, acquiring, and updating public health information systems.)
- AR-33: Plain Writing Act of 2010
- AR-34: Patient Protection and Affordable Care Act (e.g. a tobacco-free campus policy and a lactation policy consistent with S4207)

ARs applicable to HIV/AIDS Awards:

- AR-4: HIV/AIDS Confidentiality Provisions
- AR-5: HIV Program Review Panel
- AR-6: Patient Care

Organization Specific ARs:

- AR-8: Public Health System Reporting (Community-based non-governmental organizations)
- AR-15: Proof of Non-profit Status (Non-profit organizations)
- AR 23: Compliance with 45 C.F.R. Part 87 (Faith-based organizations)

Potentially Applicable Public Policy Requirements

- False or Misleading Information
- Taxes: Certification of Filing and Payment of Taxes
- Fly America Act/ U.S. Flag Air Carriers
- National Environmental Policy Act

Pilot Program for Enhancement of Employee Whistleblower Protections: All applicants will have a condition of award that applies to 48 CFR section 3.908 requiring grantees to inform their employees in writing of employee whistleblower rights and protections under 41. U.S.C 4712 in the predominant native language of the workforce.

If applicable, award recipients will be required to submit an electronic version of the final, peer-reviewed manuscript of any work developed under this award upon acceptance for publication. Additional information will be provided in the award terms.

For more information on the Code of Federal Regulations, visit the National Archives and Records Administration at: <http://www.access.gpo.gov/nara/cfr/cfr-table-search.html>

3. Reporting:

a. CDC Reporting Requirements:

Reporting allows for continuous program monitoring and identifies successes and challenges that awardees encounter throughout the project period. Also, reporting is a requirement for awardees who want to apply for yearly continuation of funding. Reporting helps CDC and awardees because it:

- Helps target support to applicants, particularly for cooperative agreements;
- Provides CDC with periodic data to monitor awardee progress towards meeting the FOA outcomes and overall performance;
- Allows CDC to track performance measures and evaluation findings for continuous program improvement throughout the project period and to determine applicability of evidence-based approaches to different populations, settings, and contexts; and
- Enables the assessment of the overall effectiveness and impact of the FOA.

As described in the following text, awardees must submit an annual performance report, ongoing performance measures data, administrative reports, and a final performance and financial report. A detailed explanation of any additional reporting requirements will be provided in the Notice of Award to successful applicants.

b. Specific Reporting Requirements:

i. Awardee Evaluation and Performance Measurement Plan:

Awardees must provide a more detailed evaluation and performance measurement plan within the first six months of the project. This more detailed plan should be developed by awardees as part of first-year project activities, with support from CDC. This more detailed plan should build on the elements stated in the initial plan, and should be no more than 25 pages. At a minimum, and in addition to the elements of the initial plan, this plan must:

- Indicate the frequency that evaluation and performance data are to be collected.
- Describe how data will be reported.
- Describe how evaluation findings will be used to ensure continuous quality and program improvement.
- Describe how evaluation and performance measurement will yield findings that will demonstrate the value of the FOA (e.g., effect on improving public health outcomes, effectiveness of FOA as it pertains to performance measurement, cost-effectiveness, or cost-benefit).
- Describe dissemination channels and audiences (including public dissemination).
- Describe other information requested and as determined by the CDC program.

When developing evaluation and performance measurement plans, applicants are encouraged to use the Introduction to Program Evaluation for Public Health Programs: A Self-Study Guide, available at: <http://www.cdc.gov/eval/guide/index.htm>

ii. Annual Performance Report:

(due no later than 120 days before the end of the budget period and serves as a continuation application).

This report must not exceed 35 pages excluding work plan and administrative reporting. Attachments are not permitted, but web links are allowed. The awardee must submit the Annual Performance Report via www.grants.gov no later than 120 days before the end of the budget period. In addition, the awardee must submit an annual Federal Financial Report within 90 days after the end of the calendar quarter in which the budget year ends.

This report must include the following:

- **Performance Measures (including outcomes)** – Awardees must report on performance measures for each budget period and update measures, if needed
- **Evaluation Results** – Awardees must report evaluation results for the work completed to date (including any impact data)
- **Work Plan (maximum of 25 pages)** – Awardees should update work plan each budget period
- **Successes**
 - ✓ Awardees must report progress on completing activities outlined in the work plan
 - ✓ Awardees must describe any additional successes (e.g., identified through evaluation results or lessons learned) achieved in the past year
 - ✓ Awardees must describe success stories
- **Challenges**
 - ✓ Awardees should describe any challenges that hinder achievement of both annual and project period outcomes, performance measures, or their ability to complete the activities in the work plan
 - ✓ Awardees must describe any additional challenges (e.g., identified through evaluation results or lessons learned) encountered in the past year
- **CDC Program Support to Awardees**
 - ✓ Awardees should describe how CDC could assist them in overcoming any challenges to achieve both annual and project period outcomes and performance measures, and complete activities outlined in the work plan
- **Administrative Reporting (not subject to page limits)**
 - ✓ SF-424A Budget Information-Non-Construction Programs
 - ✓ Budget Narrative – Must use the format outlined in Section IV. Content and Form

- of Application Submission, Budget Narrative Section
- ✓ Indirect Cost Rate Agreement
- ✓ Pipeline Analysis – Expenditures versus budget as identified in work plan, description of challenges, and explanation of unexpected pipeline (high or low).
- **Measures of Effectiveness**
 - ✓ Include progress against the numerical goals of the President’s Emergency Plan for AIDS Relief for Ethiopia and HHS/CDC guidance

iii. Performance Measure Reporting:

CDC programs must require awardees to submit performance measures annually at a minimum, and may require reporting more frequently. Performance measure reporting should be limited to the collection of data. When funding is awarded initially, CDC programs should specify reporting frequency, required data fields, and format.

iv. Monitoring Reporting and Evaluation:

CDC programs must ensure that grantee’s Evaluation and Performance Measurement Plan is aligned with the strategic information guidance established by OGAC and other HHS/CDC requirements, including PEPFAR’s Monitoring Reporting and Evaluation (MER) strategy and CDC’s Data for Partner Monitoring Program (DFPM).

v. Federal Financial Reporting:

The annual FFR form (SF-425) is required and must be submitted through eRA Commons⁴ within 90 days after the end of the calendar quarter in which the budget year ends. The report should include only those funds authorized and disbursed during the timeframe covered by the report. The final report must indicate the exact balance of unobligated funds, and may not reflect any unliquidated obligations. The final FFR expenditure data and the Payment Management System’s (PMS) cash transaction data must correspond; no discrepancies between the data sets are permitted. Failure to submit the required information by the due date may affect adversely the future funding of the project. If the information cannot be provided by the due date, awardees are required to submit a letter of explanation and include the date by which the information will be provided.

vi. Final Performance and Financial Report:

At the end of the project period, awardees must submit a final report to include a final financial and performance report. This report is due 90 days after the end of the project period. The page limit for this report is not to exceed 40 pages.

At a minimum, this report must include the following:

- Performance Measures (including outcomes) – Applicants must report final performance data for all performance measures for the project period.
- Evaluation results – Applicants must report final evaluation results for the project period
- Impact of Results – Applicants must describe the effects or results of the work completed over the project period, including success stories.
- Additional forms as described in the Notice of Award, including Equipment Inventory Report and Final Invention Statement.
- FFR (SF-425)

Awardees should e-mail the report to the CDC PO and the GMS listed in the “Agency Contacts”

⁴ <https://commons.era.nih.gov/commons/>

section of the FOA.

4. Federal Funding Accountability and Transparency Act of 2006:

Federal Funding Accountability And Transparency Act Of 2006 (FFATA), Public Law 109-282, the Federal Funding Accountability and Transparency Act of 2006 as amended (FFATA), requires full disclosure of all entities and organizations receiving Federal funds including awards, contracts, loans, other assistance, and payments through a single publicly accessible Web site, www.USASpending.gov.

Compliance with this law is primarily the responsibility of the Federal agency. However, two elements of the law require information to be collected and reported by applicants: 1) information on executive compensation when not already reported through the SAM, and 2) similar information on all sub-awards/subcontracts/consortiums over \$25,000.

For the full text of the requirements under the FFATA and HHS guidelines, go to:

- http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=109_cong_bills&docid=f:s2590enr.txt.pdf,
- https://www.fsrs.gov/documents/ffata_legislation_110_252.pdf
- http://www.hhs.gov/asfr/ogapa/aboutog/Grants%20Management%20Information/ffata_guidelines.html.

5. Programmatic Impact Reporting and Monitoring:

- A. The recipient is responsible for managing and monitoring each project, program, subaward, function or activity supported through this Agreement. Recipients must monitor subawards to ensure that subrecipients have met the programmatic impact requirements as set forth in the subrecipient's agreement.
- B. The recipient must submit the original and two copies of annual and semi-annual Performance reports and quarterly pipeline analysis reports. Annual reports must be due 90 calendar days after the award year and semi-annual and quarterly reports must be due 30 days after the reporting period. The final performance reports are due 90 calendar days after the expiration or termination of this Agreement.
- C. Performance reports must generally contain, for each award, brief information on each of the following:
 - A comparison of actual accomplishments with the goals and objectives previously established for the period, including metrics outlined in the monitoring and evaluation plan (section on M&E), any findings of an external entity, or both. Whenever appropriate and the output of programs or projects can be readily quantified, such quantitative data must be included in the reports and be related to cost data for computation of unit costs. Also included should be a brief description of the methods used to assure and assess the quality of the quantitative data, including any remediation taken to improve findings of poor data quality.
 - Reasons why established goals for the performance period were not met, if appropriate.
 - Other pertinent information including, when appropriate, statutory or Congressional reporting requirements, analysis and explanation of cost overruns or high unit costs reported in financial reports.
 - The recipient must immediately notify the awarding agency of developments that have a significant impact on the award-supported activities. Also, recipients must give notification immediately in the case of problems, delays, or adverse conditions which materially impair the ability to meet the objectives of the award. This notification must

include a statement of the action taken or contemplated, and any assistance needed to resolve the situation.

- The Pipeline Analysis report must contain expenditures versus budget as identified in work plan, description of challenges, and explanation of unexpected pipeline (high or low).

The recipient is required to submit in a timely manner quarterly, semi-annual and annual program results for all relevant programmatic indicators in accordance with U.S. government guidance.

6. Monitoring and Evaluation:

- A. The recipient must submit a monitoring and evaluation plan for approval, and carry out monitoring and evaluation activities in accordance with the approved monitoring and evaluation plan. HHS/CDC will review and approve the recipient's monitoring and evaluation plan to ensure that it is appropriate for the activities to be undertaken as part of the agreement, for compliance with the monitoring and evaluation guidance established by HHS/CDC or other guidance otherwise applicable to this Agreement.
- B. HHS/CDC or its designee will also undertake monitoring and evaluation of the defined activities within the agreement. The recipient must ensure reasonable access by HHS/CDC or its designee to all necessary sites, documentation, individuals and information to monitor, evaluate and verify the appropriate implementation the Activities and use of HHS/CDC funding under this Agreement, must require a provision to this effect in all sub-awards or contracts financed by funds under this Agreement. Where applicable, this includes support for, and response to, activities associated with the Site Monitoring System and implementation of Data and Service Quality Assessments.

7. Expenditure Analysis

Recipients of PEPFAR funds are required to report annually on program expenditures. Specifically, annual completion of PEPFAR Program Expenditures (Form DS-4213, approved by OMB 1405-0208, or the relevant OMB-approved format) will be required in conjunction with the PEPFAR Annual Progress Report at the completion of the USG fiscal year.

8. Audit, Books, and Records Clause:

- A. Reports and Information. The recipient must furnish HHS/CDC accounting records and such other information and reports relating to the Agreement as HHS/CDC may reasonably request.
- B. The Recipient Agreement Books and Records. The recipient must maintain accounting books, records, documents and other evidence relating to the Agreement, adequate to show, without limitation, all costs incurred by the recipient, the receipt and use of goods and services acquired by the recipient, agreed-upon cost sharing requirements, the nature and extent of solicitations of prospective suppliers of goods and services acquired by the recipient, the basis of award of recipient contracts and orders, and the overall progress of the Agreement toward completion ("Agreement books and records"). The recipient must maintain Agreement books and records in accordance with generally accepted accounting principles prevailing in the United States, or at the recipient's option, with approval by HHS/CDC, other accounting principles, such as those (1) prescribed by the International Accounting Standards Committee (an affiliate of the International Federation of Accountants), or (2) prevailing in the country of the recipient. Agreement books and records must be maintained for at least three years after the date of last disbursement by HHS/CDC or for such longer period, if any, required to resolve any litigation, claims or audit findings.
- C. Partner Government Audit. If \$300,000 or more of US Government funds are expended by the recipient in its fiscal year under the Agreement, the recipient must have financial audits made of the expenditures in accordance with the following terms, except as the Parties may otherwise agree in

writing:

- i. The recipient must use its Supreme Audit Institution (SAI), if the SAI is approved by HHS/CDC, or select an independent auditor to perform the audit in accordance with the guidelines issued by HHS/CDC.
 - ii. The audit must determine whether the receipt and expenditure of the funds provided under the Agreement are presented in accordance with generally accepted accounting principles agreed to in Section 2 above and whether the recipient has complied with the terms of the Agreement. Each audit must be submitted to HHS/CDC no later than nine months after the close of the recipient's year under audit.
- D. Sub-recipient Audits. The recipient, except as the Parties may otherwise agree in writing, must ensure that "covered" sub-recipients, as defined below, are audited, and submit to HHS/CDC, no later than the end of the recipient's year under audit, in form and substance satisfactory to HHS/CDC, a plan for the audit of the expenditures of "covered" sub-recipients, as defined below, that receive funds under this Agreement pursuant to a direct contract or agreement with the recipient.
- i. "Covered" sub-recipient is one who expends \$300,000 or more in its fiscal year in "US Government awards" (i.e. as recipients of US Government cost reimbursable contracts, grants or cooperative agreements).
 - ii. The plan must describe the methodology to be used by the recipient to satisfy its audit responsibilities for covered sub-recipients. The recipient may satisfy such audit responsibilities by relying on independent audits of the sub-recipients; expanding the scope of the independent financial audit of the recipient to encompass testing of sub-recipients' accounts; or a combination of these procedures.
 - iii. The plan must identify the funds made available to sub-recipients that will be covered by audits conducted in accordance with audit provisions that satisfy the recipient's audit responsibilities.
 - iv. The recipient must ensure that covered sub-recipients under direct contracts or agreements with the recipient take appropriate and timely corrective actions; consider whether sub-recipients' audits necessitate adjustment of its own records; and require each such sub-recipient to permit independent auditors to have access to records and financial statements as necessary.
- E. Audit Reports. The recipient must furnish or cause to be furnished to HHS/CDC an audit report for each audit arranged for by the recipient in accordance with this Section within 30 days after completion of the audit and no later than nine months after the end of the period under audit.
- F. Cost of Audits. Subject to HHS/CDC approval in writing, costs of audits performed in accordance with the terms of this Section may be budgeted for, and charged to, the Agreement so long as such costs are allowable, allocable, and reasonable as defined in the Cost Allowability section of this Agreement.
- G. Audit by HHS/CDC. HHS/CDC retains the right to perform the audits required under this Agreement on behalf of the recipient conduct a financial review, or otherwise ensure accountability of organizations expending US Government funds regardless of the audit requirement.
- H. Opportunity to Audit or Inspect. The recipient must afford authorized representatives of HHS/CDC the opportunity at all reasonable times to audit or inspect activities financed under the Agreement, the utilization of goods and services financed by HHS/CDC, and books, records and other documents relating to the Agreement.

- I. Sub-recipient Books and Records. The recipient will incorporate paragraphs (1), (2), (4), (5), (6), (7) and (8) of this provision into all sub-agreements with non-U.S. organizations which meet the \$300,000 threshold of paragraph (3) of this provision. Sub-agreements with non-U.S. organizations, which do not meet the \$300,000 threshold, must, at a minimum, incorporate paragraphs (7) and (8) of this provision. Sub-agreements with U.S. organizations must state that the U.S. organization is subject to the audit requirements contained in OMB Circular A-133.

9. Reporting of Foreign Taxes

- A. Valued Added Tax (VAT) and Customs Duties – Customs and import duties, consular fees, customs surtax, valued added taxes, and other related charges are hereby authorized as an allowable cost for costs incurred for non-host governmental entities operating where no applicable tax exemption exists. This waiver does not apply to countries where a bilateral agreement (or similar legal document) is already in place providing applicable tax exemptions and it is not applicable to Ministries of Health. Successful applicants will receive information on VAT requirements via their Notice of Award.
- B. The U.S. Department of State requires that agencies collect and report information on the amount of taxes assessed, reimbursed and not reimbursed by a foreign government against commodities financed with funds appropriated by the U.S. Department of State, Foreign Operations and Related Programs Appropriations Act (SFOAA) (“United States foreign assistance funds”). Outlined below are the specifics of this requirement:
 - 1) Annual Report: The grantee must submit a report on or before November 16 for each foreign country on the amount of foreign taxes charged, as of September 30 of the same year, by a foreign government on commodity purchase transactions valued at 500 USD or more financed with United States foreign assistance funds under this grant during the prior United States fiscal year (October 1 – September 30), and the amount reimbursed and unreimbursed by the foreign government. [Reports are required even if the grantee did not pay any taxes during the reporting period.]
 - 2) Quarterly Report: The grantee must quarterly submit a report on the amount of foreign taxes charged by a foreign government on commodity purchase transactions valued at 500 USD or more financed with United States foreign assistance funds under this grant. This report shall be submitted no later than two weeks following the end of each quarter: April 15, July 15, October 15 and January 15.
 - 3) Terms: For purposes of this clause:
 - “Commodity” means any material, article, supplies, goods, or equipment;
 - “Foreign government” includes any foreign government entity;
 - “Foreign taxes” means value-added taxes and custom duties assessed by a foreign government on a commodity. It does not include foreign sales taxes.
 - 4) Where: Submit the reports to the Director and Deputy Director of the CDC office in the country(ies) in which you are carrying out the activities associated with this cooperative agreement. In countries where there is no CDC office, send reports to VATreporting@cdc.gov.
 - 5) Contents of Reports: The reports must contain:
 - a. grantee name;
 - b. contact name with phone, fax, and e-mail;

- c. agreement number(s) if reporting by agreement(s);
- d. reporting period;
- e. amount of foreign taxes assessed by each foreign government;
- f. amount of any foreign taxes reimbursed by each foreign government;
- g. amount of foreign taxes unreimbursed by each foreign government.

6) Subagreements. The grantee must include this reporting requirement in all applicable subgrants and other subagreements.

10. Human Subjects Restrictions:

Data collection protocols required for release of human subjects funding restrictions must be submitted to the DGHA Science Office within 6 months of notification of such restrictions, but no later than the end of the first budget year. Requests for exceptions to these deadlines will need to be submitted in writing to the Grants Management Officer.

All protocol approvals should be obtained no later than the end of the subsequent budget period after the award or continuation has been made, provided that the Grantee has not been granted an exception to the deadlines specified above.

G. Agency Contacts

CDC encourages inquiries concerning this announcement.

For **programmatic technical assistance**, contact:

Tesfaye Desta, Project Officer
Department of Health and Human Services
Centers for Disease Control and Prevention
US Embassy
PO Box 1014 Entonto Road
Addis Ababa, Ethiopia
Telephone: +251-1130-6063
Email: hmz4@cdc.gov

For financial, awards management, or budget assistance, contact:

Dionne Bounds, Grants Management Officer
Department of Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, MS K75
Atlanta, GA 30341
Telephone: 770-488-2082
Email: vhv5@cdc.gov

For assistance with submission difficulties related to www.grants.gov, contact:

www.grants.gov Contact Center: 1-800-518-4726.

Hours of Operation: 24 hours a day, 7 days a week. Closed on Federal holidays.

For all other submission questions, contact:

Technical Information Management Section
Department of Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, MS E-14

Atlanta, GA 30341
Telephone: 770-488-2700
Email: pgotim@cdc.gov

CDC Telecommunications for individuals with hearing loss is available at: TTY 1.888.232.6348

H. Other Information

Following is a list of acceptable attachments that applicants must upload as PDF files part of their application at www.grants.gov. Applicants may not attach documents other than those listed; if other documents are attached, that document will not be reviewed.

- Project Abstract (required form)
- CDC Assurances and Certifications (required form)
- Table of Contents for Entire Submission (no page limit)
- Project Narrative/Work Plan (maximum 18 pages)
- Budget Narrative (no page limit)
- SF424 (required form)
- SF424A (required form)

Applicants may submit additional information in an Appendix. The appendices will not be counted toward the project narrative page limit. **The total amount of appendices must not exceed 90 pages.** Any pages after page 90 of the appendix will not be considered for review. The following documents must be included in the application appendices:

- **Resumes/CVs of current key staff** who will work on the activity, including, but not limited to: Principal Investigator, Business Official, Project Manager
 - **Please refer to Section D, #10, part d, “Organizational Capacity of Awardees to Execute the Approach” for specific job descriptions required in this FOA, as applicable**
- Job Descriptions of proposed key positions to be created for the activity, including, but not limited to: Principal Investigator, Business Official, Project Manager
 - **Please refer to Section D, #10, part d, “Organizational Capacity of Awardees to Execute the Approach” for specific job descriptions required in this FOA, as applicable**
- **Letters of support:** See Collaborations section and Funding Preference section, as applicable
- **Memorandums of Understanding/Agreements (MOU/MOA):** See Collaborations section and Funding Preference section, as applicable
- **Organizational Chart**
- **Negotiated Indirect Cost Rate Agreement**, if applicable
- **Non-profit organization IRS status forms**, if applicable

Any additional information submitted via www.grants.gov must be uploaded in a PDF file format, and should be clearly labeled (i.e.: Letters of support should be named “letters of support”).

Amendments, Questions and Answers (Q&As)

Applicants must submit their Q&As, if any, to the Project Officer listed under the Agency Contacts Section of this announcement no later than 15 days after the publication date in www.grants.gov. All Q&As will be published on the DGHA Website <http://www.cdc.gov/globalaids/global-hiv-aids-at-cdc/FOA.html>.

All changes, updates, and amendments to the FOA will be posted to www.grants.gov following the approval of CDC.

For additional information on reporting requirements, visit the CDC website at:
http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm.

Other CDC funding opportunity announcements can be found on Grants.gov website, at the following internet address: <http://www.grants.gov>.

I. Glossary

Administrative and National Policy Requirements, Additional Requirements (ARs): outline the Administrative requirements found in 45 CFR Part 74 and Part 92 and other requirements as mandated by statute or CDC policy. CDC programs must indicate which ARs are relevant to the FOA. All ARs are listed in the template for CDC programs. Awardees must then comply with the ARs listed in the FOA. To view brief descriptions of relevant provisions visit the CDC website at: http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm.

Authority: Legal authorizations that outline the legal basis for the components of each individual FOA. An Office of Global Council (OGC) representative may assist in choosing the authorities appropriate to any given program.

Award: Financial assistance that provides support or stimulation to accomplish a public purpose. Awards include grants and other agreements (e.g., cooperative agreements) in the form of money, or property in lieu of money, by the Federal Government to an eligible recipient.

Budget Period/Year: the duration of each individual funding period within the project period. Traditionally, budget period length is 12 months or 1 year.

Carryover: Unobligated Federal funds remaining at the end of any budget period that, with the approval of the GMO or under an automatic authority, may be carried forward to another budget period to cover allowable costs of that budget period (whether as an offset or additional authorization). Obligated, but unliquidated, funds are not considered carryover.

Catalog of Federal Domestic Assistance (CFDA): A catalog published twice a year which describes domestic assistance programs administered by the federal government. This government-wide compendium of Federal programs lists projects, services, and activities which provide assistance or benefits to the American public. <https://www.cfda.gov/index?s=agency&mode=form&id=0bebbc3b3261e255dc82002b83094717&tab=programs&tabmode=list&subtab=list&subtabmode=list>

CDC Assurances and Certifications: Standard government-wide grant application forms.

CFDA Number: The CFDA number is a unique number assigned to each program/FOA throughout its lifecycle that enables data and funding tracking and transparency.

Competing Continuation Award: An award of financial assistance which adds funds to a grant and extends one or more budget periods beyond the currently established project period.

Continuous Quality Improvement: A system that seeks to improve the provision of services with an emphasis on future results.

Contracts: An award instrument establishing a binding legal procurement relationship between CDC and a recipient obligating the latter to furnish a product.

Cooperative Agreement: An award of financial assistance that is used to enter into the same kind of relationship as a grant; and is distinguished from a grant in that it provides for substantial involvement between

the Federal agency and the awardee in carrying out the activity contemplated by the award.

Cost Sharing or Matching: Refers to program costs not borne by the Federal government but required of awardees. It may include the value of allowable third-party in-kind contributions, as well as expenditures by the awardee.

Direct Assistance: assistance given to an applicant such as federal personnel or supplies. See http://www.cdc.gov/stltpublichealth/GrantsFunding/direct_assistance.html.

Federal Funding Accountability And Transparency Act Of 2006 (FFATA): Requires information on Federal awards, including awards, contracts, loans, and other assistance and payments, be made available to the public on a single website, www.USAspending.gov.

Fiscal Year: The year that budget dollars are allocated to fund program activities. The fiscal year starts October 1st and goes through September 30th.

Grant: A legal instrument used by the Federal government to enter into a relationship, the principal purpose of which is to transfer anything of value to a recipient to carry out a public purpose of support or stimulation authorized by statute. The financial assistance may be in the form of money, or property in lieu of money. The term does not include: a Federal procurement subject to the Federal Acquisition Regulation; technical assistance (which provides services instead of money); or assistance in the form of revenue sharing, loans, loan guarantees, interest subsidies, insurance, or direct payments of any kind to individuals. The main difference between a grant and a cooperative agreement is that there is no anticipated substantial programmatic involvement by the Federal Government under an award.

Grants.gov: A "storefront" web portal for use in electronic collection of data (forms and reports) for Federal grant-making agencies through the www.grants.gov site, www.grants.gov.

Health Disparities: are differences in health outcomes and their determinants between segments of the population, as defined by social, demographic, environmental, and geographic attributes.

Healthy People 2020: Provides national health objectives for improving the health of all Americans by encouraging collaborations across sectors, guiding individuals toward making informed health decisions, and measuring the impact of prevention activities.

Inclusion: Inclusion refers to both the meaningful involvement of community members in all stages of the program process, and maximum involvement of the target population in the benefits of the intervention. An inclusive process assures that the views, perspectives, and needs of affected communities, care providers, and key partners are actively included.

Indirect Costs: Those costs that are incurred for common or joint objectives and therefore cannot be identified readily and specifically with a particular sponsored project, program, or activity but are nevertheless necessary to the operations of the organization. For example, the costs of operating and maintaining facilities, depreciation, and administrative salaries are generally treated as indirect costs.

International public health work: For purposes of this template, is defined as work conducted internationally for the benefit of a foreign entity or jurisdiction.

Lobbying: Direct lobbying includes any attempt to influence legislation, appropriations, regulations,

administrative actions or Executive Orders (“legislation or other orders”), or other similar deliberations at all levels of government through communications that directly express a view on proposed or pending legislation or other orders and which are directed to members of staff, or other employees of a legislative body or to government officials or employees who participate in the formulation of legislation or other orders. Grass Roots lobbying includes efforts directed at inducing or encouraging members of the public to contact their elected representatives at the Federal, State or local levels to urge support of, or opposition to, proposed or pending legislative proposals.

Maintenance of Effort: A requirement contained in authorizing legislation, regulation stating that to receive Federal grant funds a recipient must agree to contribute and maintain a specified level of financial effort for the award from its own resources or other non-Federal sources. This requirement is typically given in terms of meeting a previous base-year dollar amount.

Memorandum of Understanding (MOU)/Memorandum of Agreement (MOA): is a document describing a bilateral or multilateral agreement between parties. It expresses a convergence of will between the parties, indicating an intended common line of action. It is often used in cases where parties either do not imply a legal commitment or in situations where the parties cannot create a legally enforceable agreement.

New FOA: Any FOA that is not a continuation or supplemental award.

Non-Governmental Organization: A non-governmental organization (NGO) is any non-profit, voluntary citizens' group which is organized on a local, national or international level.

Notice of Award: The only binding, authorizing document between the recipient and CDC confirming issue of award funding. The NoA will be signed by an authorized Grants Management Officer, and provided to the recipient fiscal officer identified in the application.

Objective Review: A process that involves the thorough and consistent examination of applications based on an unbiased evaluation of scientific or technical merit or other relevant aspects of the proposal. The review is intended to provide advice to the individuals responsible for making award decisions.

OGC: Office of the General Counsel (OGC) is the legal team for the Department of Health and Human Services (HHS), providing representation and legal advice on a wide range of national issues. OGC supports the development and implementation of HHS's programs by providing legal services to the Secretary of HHS and the organization's various agencies and divisions.

Outcome: The observable benefits or changes for populations and/or public health capabilities that will result from a particular program strategy.

Performance Measures: Performance measurement is the ongoing monitoring and reporting of program accomplishments, particularly progress toward pre-established goals. It is typically conducted by program or agency management. Performance measures may address the type or level of program activities conducted (process), the direct products and services delivered by a program (outputs), or the results of those products and services (outcomes). A “program” may be any activity, project, function, or policy that has an identifiable purpose or set of objectives.

Plain Writing Act of 2010: The Plain Writing Act requires federal agencies to communicate with the public in plain language to make information and communication more accessible and understandable by intended users, especially people with limited health literacy skills or limited English proficiency. www.plainlanguage.gov

Procurement and Grants Office (PGO): PGO is the only entity within CDC which can obligate federal funds. PGO provides non-programmatic management for all CDC financial assistance activities (grants and cooperative agreements) and manages and awards all CDC contracts.

Program Strategies: Public health interventions or public health capabilities.

Program Official: The person responsible for developing the FOA – whether a project officer, program manager, branch chief, division leadership, policy official, center leadership, or similar staff member.

Project Period Outcome: An outcome that will result by the end of the FOA period of funding.

SAM: The System for Award Management (SAM) is the primary vendor database for the U.S. Federal Government. SAM validates applicant information and electronically shares the secure and encrypted data with the Federal agencies' finance offices to facilitate paperless payments through Electronic Funds Transfer (EFT). The SAM stores organizational information, allowing www.grants.gov to verify your identity and to pre-fill organizational information on grant applications.

Statute: An act of a legislature that declares, proscribes, or commands something; a specific law, expressed in writing. A statute is a written law passed by a legislature on the state or federal level. Statutes set forth general propositions of law that courts apply to specific situations.

Statutory Authority: A legal statute that provides the authority to establish a Federal financial assistance program or award.

Technical Assistance: The providing of advice, assistance, and training pertaining to the development, implementation, maintenance, and/or evaluation of programs.

Work Plan: The summary of annual strategies and activities, personnel and/or partners who will complete them, and the timeline for completion. The work plan will outline the details of all necessary activities that will be supported through the approved budget.